International Hepatology Communications

New approaches to the treatment of acute liver failure, including the bioartificial liver
pp. 1-1(1)
Author: Williams R.

Recent advances in targeted gene therapy for liver diseases
pp. 1-1(1)
Authors: Wu G.Y.; Wu C.H.

Clinical significance of quantitation of hepatitis C virus (HCV) core antigen in serum
pp. 2-2(1)
Authors: Tanaka T.; Tanaka S.; Tanaka E.; Kiyosawa K.; Mizokami M.; Hasegawa A.; Kashiwakuma T.; Ohta Y.; Hattori N.; Kohara K.; Lau J.; Kohara M.

Electron microscopic study on virus-like particles in plasma samples from blood donors with non-A, non-B hepatitis (V) - distribution of E1 and E2/NS1 antigens on HCV particles -
pp. 2-2(1)
Authors: Kaito M.; Watanabe S.; Tsukiyama-Kohara K.; Ishida S.; Kobayashi Y.; Kondo M.; Fujita N.; Kato H.; Shima T.; Suzuki S.; Kohara M.

Gene therapy targeting HCV-RNA and development of the technique for in vivo analysis of HCV-RNA cleavage in gene therapy
pp. 2-2(1)
Authors: Yamada S.; Tanaka E.; Kiyosawa K.; Furuta S.

Expression of hepatitis C virus envelope proteins in transgenic mice
pp. 2-2(1)
Authors: Koike K.; Moriya K.; Ishibashi K.; Matsuura Y.; Suzuki T.; Yotsuyanagi H.; Shintani Y.; Saito I.; Iino S.; Kurokawa K.; Miyamura T.

Mutations in the precore/core promoter of hepatitis B virus and their clinical significance
pp. 3-3(1)
Authors: Okamoto H.; Moriyama K.; Sato S.

A minimal and optimal epitope of HLA B44-restricted HCV-specific CTL
pp. 3-3(1)
Authors: Kita H.; Moriyama T.; Kaneko T.; Hiroishi K.; Ohnishi S.; Yazaki Y.; Imawari M.

Molecular cloning of rat hepatocyte growth factor (HGF)-activator and its expression following hepatic injury
pp. 3-3(1)
Authors: Okajima A.; Sakitani K.; Miyazaki H.; Kadota Y.; Kuno K.; Ueno Y.; Naito Y.; Inoue K.; Miyazawa K.; Kitamura N.

Gene expression of lysyl oxidase in CCl₄-induced liver injury
pp. 3-3(1)
Authors: Furui K.; Takahara T.; Ito H.; Nakayama Y.; Miyabayashi C.; Higuchi K.; Watanabe A.; Ooshima A.

Role of albumin and HDL as endotoxin binding proteins: effect of alcohol
pp. 4-4(1)
Authors: Kitano H.; Fukui H.; Kikuchi E.; Matsumoto M.; Kikukawa M.; Morimura M.; Tsujita S.; Nagamoto I.; Nakatani T.; Tsujii T.; Okamoto Y.

Gene therapy:application to the treatment of hepatocellular carcinoma
pp. 4-4(1)
Authors: Kaneko S.; Matsushita E.; Y. C.; Hallenbeck P.; Kotani T.; Tamaoki T.; Nakabayashi H.; Unoura M.; Kobayashi K.; Anderson W.F.

A novel compound of polyprenoic acids reduced recurrence rates of hepatocellular carcinoma: a double-blind controlled clinical trial
pp. 4-4(1)
Authors: Muto Y.; Moriwaki H.; Ninomiya M.; Adachi S.; Saito A.; Takasaki T.; Tanaka T.; Tsurumi K.

Hydroxyethyl adducts in rat liver microsomes: role in alcoholic liver disease pathogenesis.
pp. 4-4(1)
Authors: French S.; Morimoto M.; Ingelman-Sundberg M.; Albano E.

Recent research progress in Japan
pp. 5-5(1)
Author: Muto Y.

Molecular and cellular pathogenesis of acute fatal hepatitis in HBV transgenic mouse
pp. 5-5(1)
Authors: Ando K.; Chisari F.V.

Fas system-mediated liver cell death in type C hepatitis
pp. 5-5(1)
Authors: Hayashi N.; Mita E.; Mochizuki K.; Katayama K.; Kasahara A.; Fusamoto H.; Kamada T.

Analysis of cytokine cascade for P.acnes/LPS induced liver apoptosis
pp. 5-5(1)
Authors: Matsui K.; Hirose S.; Higashino K.; Nakanishi K.; Tsutsui H.; Shinka S.

Recent progress in research for hepatocyte growth factor
pp. 6-6(1)
Author: Tsubouchi H.

Transcriptional control of liver regeneration.
pp. 6-6(1)
Author: Taub R.

Possible difference in the role of transforming growth factor and hepatocyte growth factor in liver regeneration
pp. 6-6(1)
Authors: Tomiya T.; Ogata I.; Fujiwara K.

Hepatocyte growth factor-like/macrophage stimulating protein
pp. 6-6(1)
Author: Harrison P.M.

Gene expression of matrix metalloproteinase and its inhibitor in regenerating liver after partial hepatectomy --comparison with repair process in CCl4-injured liver--.
pp. 7-7(1)
Authors: Takahara T.; Furui K.; Funaki J.; Itoh H.; Nakayama Y.; Satoh H.; Watanabe A.

Strategies for prevention of viral hepatitis in the United States.
pp. 8-8(1)
Author: Holland P.

Epidemiology of viral hepatitis and hepatocellular carcinoma in Italy
pp. 8-8(1)
Author: Craxi A.

Seroepidemiology of HBV and HCV in India and strategy for its control
pp. 8-8(1)
Authors: Tandon B.N.; Acharya S.K.; Tandon A.

Seroepidemiology of HBV/HCV in Pakistan
pp. 8-8(1)
Author: Zuberi S.J.

Seroepidemiology of HBV and HCV in Bangladesh
pp. 9-9(1)
Author: Khan M.

Seroepidemiology of viral hepatitis B and C in Indonesia
pp. 9-9(1)
Author: Suwignyo S.

National stragies for viral hepatitis B & C and HCC in Taiwan
pp. 9-9(1)
Author: J. L.S.

Seroepidemiology of HBV and HCV and the decreasing prevalence rate of HBsAG after launching HB vaccination program in Korea.
pp. 9-9(1)
Authors: H-S L.; Cy K.

Sero-epidemiological study of HBV and HCV infection in P. R. China
pp. 10-10(1)
Authors: Xia G.-L.; Liu C.-B.; Cao H.-L.; Bi S.-L.; Zhan M.-Y.

Mother-to-infant transmission of hepatitis B virus and its prevention in Japan
pp. 10-10(1)
Author: Shiraki K.

Efficacy of blood screening on the incidence of post-transfusion hepatitis in Japan
pp. 10-10(1)
Author: Yoshizawa H.

Overview of recent progress in alcoholic liver disease.
pp. 11-11(1)
Author: Lumeng L.

Recent trend in research of alcoholic liver disease in Japan
pp. 11-11(1)
Author: Ishii H.

Metabolism of acetaldehyde to acetate by rat hepatic P450S; a different metabolic pathway from ALDH system
pp. 11-11(1)
Authors: Kunitoh S.; Tanaka T.; Asai H.; Yamada T.; Imaoka S.; Hiroi T.; Monna T.; Funae Y.

Polymorphisms in alcohol dehydrogenase 2 gene and alcoholic organ injuries in Japanese alcoholics
pp. 11-11(1)
Authors: Yamauchi M.; Maezawa Y.; Searashi Y.; Kawashima O.; Takeda K.; Mizuhara Y.; Ohata M.; Toda G.

Enhancement of ADP-ribosylation of the stimuratory GTP-binding protein after alcohol intake in rat liver plasma membranes
pp. 12-12(1)
Authors: Nomura F.; Noda M.; Nakai T.

Role of nutrition in alcoholic liver disease
pp. 12-12(1)
Author: French S.

Role of endotoxin in alcoholic liver disease
pp. 12-12(1)
Authors: Kato S.; Kurose I.; Ishii H.

Microcirculatory disturbance in alcoholic liver disease
pp. 12-12(1)
Authors: Takei Y.; Oshita M.; Hijioka T.; Kawano S.; Fusamoto H.; Kamada T.

Role of cytokines and Ito cells in hepatic fibrosis.
pp. 13-13(1)
Authors: Tsukamoto H.; Kamimura S.; Lin M.

Progress in the treatment of alcoholic liver disease.
pp. 13-13(1)
Author: Lieber C.S.

Intrahepatic haemodynamics in portal hypertension
pp. 14-14(1)
Authors: Grossman V.; Grossman H.; Bhathal P.

A study of portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy
pp. 14-14(1)
Authors: Hashizume H.; Ohta M.; Kawanaka H.; Kishihara F.; Tomikawa M.; Tanoue K.; Higashi H.; Sugimachi K.

Intestinal hemodynamics in portal hypertension
pp. 14-14(1)
Authors: Joh T.; Itoh M.

Gastric microcirculatory changes in portal hypertension, pathophysiological rationale for clinical treatment.
pp. 14-14(1)
Author: Pique J.M.

Large gastric varices protect development of portal-hypertensive gastropathy: a study of 510 cirrhotic patients
pp. 15-15(1)
Authors: Iwao T.; Toyonaga A.

Membrane studies in cirrhotic cardiomyopathy.
pp. 15-15(1)
Authors: Lee S.S.; Ma Z.; Miyamoto A.; Jaue D.; Meddings J.B.

Effects on gastric circulation following the treatments for portal hypertension in cirrhosis
pp. 15-15(1)
Authors: Sezai S.; Sakurabayashi S.; Suzuki T.; Yamamoto Y.; Abe K.; Yoshino K.; Hirano M.; Iwase T.; Oka H.

Current status of treatment liver disease in our unit and future perspective
pp. 16-16(1)
Author: Omata M.

Therapy of chronic viral hepatitis.
pp. 16-16(1)
Author: Hoofnagle J.

Treatment of hepatitis in Asia and future perspectives
pp. 16-16(1)
Author: Liaw Y.F.

Nucleic acid based therapy of viral hepatitis.
pp. 16-16(1)
Authors: Wands J.R.; Moradpour D.; Tokushige K.; Melegari M.; Scaglioni P.; Wakita T.

Predictors of response to interferon and therapeutic options in chronic hepatitis C
pp. 17-17(1)
Author: Alberti A.

Non-surgical treatment of hepatocellular carcinoma and future perspectives
pp. 17-17(1)
Author: Shiina S.

Liver transplantation in the United States
pp. 17-17(1)
Author: Rakela J.

Adoptive transfer of immunity to hepatitis B
pp. 17-17(1)
Author: D. S.

An overview of diagnostic imaging of hepatocellular carcinoma (introduction)
pp. 18-18(1)
Author: Ichida T.

Differential diagnosis of small liver tumors by CT, MRI and angiography
pp. 18-18(1)
Author: Matsui O.

Use of color Doppler energy in the diagnosis of small liver tumor
pp. 18-18(1)
Authors: Saito A.; Katagiri S.; Sugimoto C.; Niinami C.; Takasaki K.; Hayashi N.

Diffuse liver disease: diagnosis by MR imaging
pp. 18-18(1)
Author: Mitchell D.G.

Imaging findings in cirrhosis-correlation with ex-vivo liver specimens
pp. 19-19(1)
Author: Dodd G.D.

Functional imaging of the liver via receptor-binding radiopharmaceuticals
pp. 19-19(1)
Authors: Vera D.R.; Stadalnik R.C.; Pimstone N.R.

Imaging for asialoglycoprotein receptor: functional evaluation
pp. 19-19(1)
Authors: Kudo M.; Todo A.; Ikekubo K.; Vera D.R.; Stadalnik R.C.

Hemodynamic imaging of the liver in various liver diseases
pp. 19-19(1)
Author: Moriyasu F.

Recent developments in the cellular and molecular basis of bile formation
pp. 20-20(1)
Author: Boyer J.L.

Ultrastructural features of bile formation
pp. 20-20(1)
Author: Sakisaka S.

Hepatic mechanisms for canalicular secretion of bile salts and phospholipid
pp. 20-20(1)
Authors: Crawford J.; Crawford A.; Hatch V.; Barnes S.; Godleski J.

Bile acid transport in hepatocytes
pp. 20-20(1)
Author: Takikawa H.

Bile canalicular contraction and bile formation.
pp. 21-21(1)
Authors: Watanabe S.; Sato N.

Hepatic metabolism and transport of bilirubin and other organic anions
pp. 21-21(1)
Author: Adachi Y.

Evidence for the involvement of vesicular transport in canalicular bile formation-time lapse, cinematographic microfluometric and electron cytochemical analysis
pp. 21-21(1)
Authors: Oda M.; Kamegaya Y.; Kazemoto S.; Tsukada N.; Yokomori H.; Ishii H.

Effects of bile acids on the microtubule-dependent motor, kinesin, purified from rabbit liver.
pp. 21-21(1)
Authors: Kuramitsu T.; Komatsu M.; Funaoka M.; Ono T.; Hoshino T.; Kato J.; Ishii T.; Masamune O.

Trageted inhibition of type I procollagen synthesis by antisense DNA oligonucleotides.
pp. 22-22(1)
Authors: C. H.W.; Walton C.M.; G. Y.W.

Transcriptional activation of 2(I) collagen promoter following acute liver injury-analysis using transgenic mouse-
pp. 22-22(1)
Authors: Inagaki Y.; Nemoto T.; Kawai H.; Unoura M.; Kobayashi K.

The role of Ito cells in hepatic fibrosis and portal hypertension
pp. 22-22(1)
Author: Pinzani M.

TGF- and hepatic fibrosis
pp. 22-22(1)
Authors: Zern M.A.; Santos R.; Degli Esposti S.

Cloning and characterization of newly described cDNAS from a fat-storing cell library: possible markers for transformation of fat-storing cells into myofibroblasts.
pp. 23-23(1)
Authors: Ogata I.; Matsui A.; Greenwel P.; Geerts A.; Suzuki K.; Fujiwara K.; Rojkind M.

Retinoic acid induces biphasic release and activation of latent transforming growth factor- in rat stellate cell cultures
pp. 23-23(1)
Authors: Koda H.; Okuno M.; Moriwaki H.; Imai S.; Muto Y.; Kojima S.; Kawada N.

Mechanism of Ito cell activation in rat liver cirrhosis induced by a choline-deficient (CD) diet and prevention of Ito cell activation by prolyl 4-hydroxylase inhibitor
pp. 23-23(1)
Authors: Sakaida I.; Matsumura Y.; Wasaki S.; Nagatomi A.; Tamura K.; Kimura T.; Yasunaga M.; Okita K.

Serum markers in hepatic fibrosis
pp. 23-23(1)
Authors: Murawaki Y.; Kawasaki H.

The significance of serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic liver disease
pp. 24-24(1)
Authors: Okazaki Y.; Watanabe N.; Kagawa T.; Wasada M.; Nagata N.; Uchiyama J.; Nakano A.; Nisizaki Y.; Wada N.; Arai M.; Okazaki I.; Maruyama K.; Matsuzaki S.

Hepatocellular carcinoma in Japan
pp. 25-25(1)
Author: Okita K.

Percutaneous acetic acid injection (PAI) for small hepatocellular carcinoma (HCC) in comparison with percutaneous ethanol injection (PEI).
pp. 25-25(1)
Authors: Ohnishi K.; Yoshioka H.; Yamagishi F.; Itoh S.; Fujiwara K.

Present status of treatment of small hepatocellular carcinoma
pp. 25-25(1)
Authors: Tanaka M.; Tanikawa K.

Percutaneous microwave coagulation therapy for hepatocellular carcinoma (HCC).
pp. 25-25(1)
Authors: Seki T.; Wakabayashi M.; Nakagawa T.; Itho T.; Imamura M.; Shiro T.; Inoue K.

Segmental necro-sclerotherapy for hepatocellular carcinoma (HCC)
pp. 26-26(1)
Authors: Iwasaki T.; Chida N.; Suzuki S.; Akahane T.; Kobayashi N.; Takahashi N.; Tanabe N.; Gama H.; Ishii M.; Toyota T.

Present status of treatment of large hepatocellular carcinoma
pp. 26-26(1)
Authors: Kurokawa F.; Yamasaki T.; Yasunaga M.; Okita K.

Surgical treatment of small presymptomatic hepatocellular carcinoma
pp. 26-26(1)
Authors: Z. Y.T.; Y. Q.Y.; X. D.Z.; Z. C.M.

Hepatocellular carcinoma: differences between Japan and black Africa
pp. 26-26(1)
Author: Kew M.C.

Cancer chemotherapy of hepatocellular carcinoma
pp. 27-27(1)
Authors: Falkson G.; Falkson H.C.

Long-term effect of proton irradiation for hepatocellular carcinoma
pp. 27-27(1)
Authors: Yoshiga S.; Matsuzaki Y.; Saito Y.; Ikegami T.; Abei M.; Shoda J.; Tanaka N.; Chiba T.; Okumura T.; Tsuji H.; Itai Y.; Tsujii H.; Osuga T.

A new combination therapy for unresectable hepatocellular carcinoma.
pp. 27-27(1)
Authors: Beppu T.; Katafuchi S.; Yamanaka Y.; Egami H.; Masuda Y.; Kudo S.; Doi K.; Ogawa M.

Overview: etiology and pathophysiology of liver abscess.
pp. 28-28(1)
Authors: Tsutsumi V.; Shibayama-Salas M.; Ventura-Juarez J.; Martinez-Palomo A.

Iatrogenic liver abscess: mechanism and characteristics
pp. 28-28(1)
Authors: Kinoshita H.; Kubo S.; Hirohashi K.; Tanaka H.; Tsukamoto T.; Takemura S.

Current status of liver abscess in Japan
pp. 28-28(1)
Authors: Uchino J.; Saji Y.; Kamiyama T.; Nakanishi K.

Current status on the treatment of amebic liver abscess
pp. 28-28(1)
Author: Romero-Cabell R.

Alveolar echinococcosis of the liver: pathogenesis and treatment
pp. 29-29(1)
Authors: Sato N.; Uchino J.; Une Y.; Nakajima Y.; Matsushita M.; Takahashi M.; Aoki S.; Kamiyama T.; Shimamura T.; Nakanishi K.; Haneda T.; Takahashi H.; Matsuhisa T.

Clinical aspects of patients with schistosomiasis japonica and its care
pp. 29-29(1)
Authors: Matsumoto Y.; Inoue S.; Yoshioka M.; Itakura J.; Matsuda M.; Nagahori K.; Yamamoto M.

Pathogenesis and treatment of granulomatous liver abscess
pp. 29-29(1)
Authors: Noguchi T.; Yamagiwa K.; Yokoi H.; Kawarada Y.

The five cases of hepatic eosinophilic abscess
pp. 29-29(1)
Authors: Sang-Yong S.; Sang-Hyuk L.; Jung-Myung C.; Sang-Suk H.; Ha-Jin C.

Nonsurgical therapy of liver abscess and it's limit
pp. 30-30(1)
Author: Yoshida H.

Solitary and multiple liver abscesses: backgrounds of the patients and the efficacy of percutaneous drainage.
pp. 30-30(1)
Authors: Tazawa J.; Hirata R.; Sakai Y.; Yauchi T.; Hattori K.; Maeda M.; Marumo F.; Sato C.

Treatment for type-B chronic hepatitis
pp. 31-31(1)
Author: Kumada H.

Current state of treatment for chronic hepatitis C in Japan
pp. 31-31(1)
Author: Iino S.

Combination therapy of ribavirin plus interferon aifa for chronic hepatitis C
pp. 31-31(1)
Authors: M. Y.L.; J. H.K.; P. M.Y.; J. T.W.; P. J.C.; J. L.S.; D. S.C.

Clinical significance of quantitative analysis of virus markers and mutants in therapeutic decisions
pp. 31-31(1)
Authors: Brunetto M.; Flichman D.; Randone A.; Bonino F.

Serum hepatitis C virus core protein level as predictor of response to interferon-alfa therapy
pp. 32-32(1)
Authors: Mizokami M.; Orito E.

RNA sequences related to the effect of interferon in chronic hepatitis C: hypervariable region (HVR)
pp. 32-32(1)
Authors: Akahane Y.; Okada S.; Sakamoto M.; Naitoh S.; Takeda K.; Ainota T.; Miyazaki Y.

Prediction of response to interferon by typing NS5A region in chronic HCV-1B infection
pp. 32-32(1)
Authors: Enomoto N.; Sakuma I.; Asahina Y.; Kurosaki M.; Murakami T.; Yamamoto C.; Izumi N.; Marumo F.; Sato C.

Clinical usefulness of low dose oral interferon for the treatment of chronic hepatitis B
pp. 32-32(1)
Authors: Yasuda K.; Iino S.

New drugs to chronic hepatitis: slow-release interferon
pp. 33-33(1)
Author: Matsushima T.

Usefulness of imiquimod in chronic hepatitis C.
pp. 33-33(1)
Authors: Nishiyama Y.; Hino K.; Iino S.

Treatment of chronic hepatitis C
pp. 33-33(1)
Authors: Bonino F.; Oliveri F.; Baldi M.; Colombatto P.; Flichman D.; Brunetto M.

Overview of cadaveric liver transplantation
pp. 34-34(1)
Author: Lynch S.V.

Overview on living-related liver transplantation
pp. 34-34(1)
Author: Makuuchi M.

Living related liver transplantation: a review of 150 recipients
pp. 34-34(1)
Authors: Tanaka K.; Uemoto S.; Inomata Y.; Ozaki N.; Satomura K.; Egawa H.; Kiuchi T.; Yamaoka Y.

Living related partial liver transplantation (LRLT) in adult patients
pp. 34-34(1)
Authors: Kawasaki S.; Matsunami H.; Hashikura Y.; Ikegami T.; Nakazawa Y.; Miyagawa S.; Kiyosawa K.; Makuuchi M.

Confucianism and organ donation in korea
pp. 35-35(1)
Author: Soo Tae K.

Open the door for organ donation in the far east with Hong Kong University experience.
pp. 35-35(1)
Author: S. T.F.

Hepatocyte transplantation in multi-locations of congenitally enzyme deficient rats
pp. 35-35(1)
Authors: Nakazawa F.; Onodera K.; Kato K.; Sawa M.; Kasai S.; Mito M.; Matsushita T.; Funatsu K.

The interaction between hepatic sinusoidal cells causing graft dysfunction in liver transplantation
pp. 35-35(1)
Authors: Sakurai H.; Kitagawa M.; Noguchi T.; Kawarada Y.

Intravascular coagulation in the hepatic sinusoids induced by gut-derived substances may cause liver injury following orthotopic liver transplantation (OLTX) in rats
pp. 36-36(1)
Authors: Arai M.; Mochida S.; Ohno A.; Fujiwara K.

Viability of partial liver graft from living donor in pig -comparative study with whole liver graft from cadaver-
pp. 36-36(1)
Authors: Ohkohchi N.; Hirano T.; Katoh H.; Endoh T.; Orii T.; Satomi S.; Mori S.

Etiology of fulminant viral hepatitis in urban area of Japan - multicenter study
pp. 37-37(1)
Authors: Yoshiba M.; Sekiyama K.; Inoue K.; Koh I.; Nagai K.; Kako M.; Takatori M.; Iwabuchi I.; Sumino Y.; Sugimoto M.; Hakozaki S.; Tanaka K.; Sekihara H.

The recent increase of severe type a hepatitis in Chiba area
pp. 37-37(1)
Authors: Fujiwara K.; Ehata T.; Yokosuka O.; Imazeki F.; Ohto M.; Ohtake Y.; Sugai T.; Hirasawa H.

Detection of hepatitis a virus in serum by PCR method
pp. 37-37(1)
Authors: Naito Y.; Fujise K.; Niiya M.; Takahasi H.; Isikawa T.; Inoue T.; Satoh S.; Kawamata O.; Totsuka A.; Watanabe R.; Kawaguchi R.; Moritsugu Y.

Prevalence of hepatitis E virus markers in patients with acute hepatitis in Japan
pp. 37-37(1)
Authors: Fukushima S.; Okuno H.; Hirota T.; Kadota Y.; Shiozaki S.; Inoue K.; Huang R.T.; Nakazono N.

Clinical significance of antibody to E2NS1 in patients with acute hepatitis C.
pp. 38-38(1)
Authors: Kobayashi M.; Tanaka E.; Matsumoto A.; Kobayashi M.; Suzuki T.; Urushihara A.; Imai H.; Sodeyama T.; Kiyosawa K.; Furuta S.

Clinicopathological study in infants with hepatitis due to cytomegalovirus infection.
pp. 38-38(1)
Authors: Nakashima E.; Inoue T.; Yamashita Y.; Ushijima K.; Kimura A.; Fujisawa T.; Kosai K.; Ogasawara S.; Kage M.

Double blind placebo controlled trial of a herbal drug combination (Jigreen) in patients of acute viral hepatitis.
pp. 38-38(1)
Authors: Habibullah C.M.; Hassan S.I.; Quddus M.A.; Humaira S.; Naseem B.; Rao V.

Clinical and histological studies in idiopathic neonatal hepatitis of non-familial form
pp. 38-38(1)
Authors: Tazawa Y.; Konno T.

Mutations in the core promoter/enhancer II regions of naturally occurring Hepatitis B virus variants and analysis of the effects on transcription activities
pp. 39-39(1)
Authors: Nishizono A.; Hiraga M.; Kohno K.; Sonoda Y.T.; Terao H.; Fujioka T.; Nasu M.; Mifune K.

Analysis of changes in hepatitis B virus genomes after acute exacerbation of chronic hepatitis B
pp. 39-39(1)
Authors: Asahina Y.; Enomoto N.; Kurosaki M.; Sakuma I.; Ogura Y.; Hoshino Y.; Izumi N.; Tozuka S.; Marumo F.; Sato C.

Mutations in the core promoter region of HBV genome are associated with hepatocellular injury in chronic HBV carriers.
pp. 39-39(1)
Authors: Kurosaki M.; Enomoto N.; Asahina Y.; Sakuma I.; Tei K.; Kobayashi F.; Ikeda T.; Tozuka S.; Sakamoto S.; Izumi N.; Okaniwa M.; Marumo F.; Sato C.

Clinical implications and an easy method for detection of the precore/core promoter mutant (T¹⁷⁶² A¹⁷⁶⁴) of hepatitis B virus
pp. 39-39(1)
Authors: Ohno N.; Aoyama K.; Iwata K.; Yoshizawa H.; Takahashi K.

Clinical significance of mutations in the core promoter of hepatitis B virus
pp. 40-40(1)
Authors: Sugai Y.; Nakayama H.

The study of the correlation between the pathogenesis and the deletion mutant of HBV core lesion
pp. 40-40(1)
Authors: Sugata F.; Yasuda K.; Shibahara K.; Iino S.

Hepatitis B virus variants: protective efficacy of licensed vaccines against infection with a surface mutant which emerged in an immunized infant
pp. 40-40(1)
Authors: Ogata N.; Zanetti A.R.; Miller R.H.; Purcell R.H.

Mechanisms of clearance of HBs antigen and following viral persistence in the patients with chronic hepatitis B
pp. 40-40(1)
Authors: Kato J.; Hasegawa K.; Toii N.; Shizuma T.; Yamauchi K.; Hayashi N.

Dual and triple infection with HCV: a clinicopathological study
pp. 41-41(1)
Authors: R. N.C.; S. F.C.; C. M.C.; I. S.S.; S. L.T.; Y. F.L.

Emergence of precore mutant selected by immune clearance of HBV
pp. 41-41(1)
Authors: C. T.C.; C. T.Y.; S. L.T.; I. S.S.; C. M.C.; Y. F.L.

Novel hepatitis B variants in siblings carrier positive for anti-HBs
pp. 41-41(1)
Authors: Kobayashi M.; Chayama K.; Tsubota A.; Suzuki Y.; Arase Y.; Koida I.; Saitoh S.; Murashima N.; Ikeda K.; Kumada H.; Kobayashi M.; Koike H.; Hashimoto M.

Sequencing analysis of the terminal protein region of the polymerase gene in chronic HBV infection.
pp. 41-41(1)
Authors: Ohkawa K.; Hayashi N.; Yuki N.; Mita E.; Masuzawa M.; Kato M.; Sasaki Y.; Kasahara A.; Fusamoto H.; Kamada T.

Genetic drift of hepatitis B virus precore/core region in long-term follow-up of asymptomatic HBe-Ag-positive carriers
pp. 42-42(1)
Authors: Tsubota A.; Chayama K.; Arase Y.; Koida I.; Saitoh S.; Ikeda K.; Murashima N.; Suzuki Y.; Kobayashi M.; Takagi K.; Hashimoto M.; Kobayashi M.; Kumada H.

Clinical significance of deletion in the pre-S region of HBV DNA.
pp. 42-42(1)
Authors: Kobayashi T.; Niitsuma H.; Itoh K.; Saitoh Y.; Miura M.; Kobayashi K.; Ishii M.; Toyota T.

Distinguishing between acute and chronic hepatitis B virus infection
pp. 42-42(1)
Authors: Maruyama T.; Iino S.; Koike K.; Yasuda K.; Hashimoto N.; Yotsuyanagi H.; Moriya K.; Shintani Y.; Yamada H.; Han K.; Kurokawa K.; Kashiwagi M.; Milich D.R.

HBVs with mutations in the encapsidation signal observed in HBV carriers are potent in packaging of pregenomic RNA.
pp. 42-42(1)
Authors: Itoh K.; Niitsuma H.; Kobayashi T.; Saitoh Y.; Miura M.; Kobayashi K.; Ishii M.; Toyota T.

Sequence variations at encapsidation signal and serum alanin aminotransferase in anti-HBe positive HBV carriers.
pp. 43-43(1)
Authors: Niitsuma H.; Miura M.; Kobayashi T.; Itoh K.; Saitoh Y.; Kobayashi K.; Ishii M.; Toyota T.

The pre S domain is the major determinant of hepadnaviral host range
pp. 43-43(1)
Authors: Ishikawa T.; Ganem D.

Bidirectional promoter complex within the X gene of hepatitis B virus and woodchuck hepatitis virus
pp. 43-43(1)
Authors: Shimoda A.; Miller R.H.; Kaneko S.; Unoura M.; Kobayashi K.; Purcell R.H.

A new method for RNA extraction-agglutination partition method- for diagnosis of type chronic hepatitis
pp. 43-43(1)
Authors: Hasebe C.; Kawashima T.; Sekiya C.; Torimoto Y.; Fujimoto Y.; Mizuno M.; Nishimori H.; Kohda H.; Yazaki Y.; Kohgo Y.; Usui M.; Yamaguchi M.

Development of strand specific RT-PCR method and its application for detection of the HCV negative strand RNA
pp. 44-44(1)
Authors: Narui J.; Katayama K.; Hoshino F.B.; Fukushi S.; Ishiyama N.; Saito S.; Kikuchi S.; Ando T.; Oya A.

Quantitative measurement of HCV RNA by AMPLICOR and its clinical application
pp. 44-44(1)
Authors: Ichijo T.; Matsumoto A.; Kobayashi M.; Chi E.; Tanaka E.; Kiyosawa K.; Furuwatari C.; Ueno I.; Furihata K.

Antibody-free hepatitis C virus measured by immunoabsorbed multicyclic RT-PCR may provide new information on the condition of chronic hepatitis C patients
pp. 44-44(1)
Authors: Kurihara C.; Katayama K.; Ishiyama N.; Fukushi S.; Hoshino F.B.; Ando T.; Oya A.

Quantitation of serum HCV core protein level in patients with various HCV genotypes
pp. 44-44(1)
Authors: Orito E.; Mizokami M.; Ohba K.; Ohno T.; Koide T.; Tanaka T.; Tanaka S.; Tanaka E.; Kiyosawa K.; Ohta Y.; Hasegawa A.; Kohara M.

Porphyria cutanea tarda and HCV infection
pp. 45-45(1)
Authors: Kondo M.; Horie V.; Okano J.; Kawasaki U.; Mishiro S.; Yamamoto S.; Okamoto H.

Comparison of HCV-RNA concentrations and variations of E2/NS1 regions between before and after aids occurence in a patient with hemophilia A and hepatitis C
pp. 45-45(1)
Authors: Kobayashi M.; Kitano Y.; Tanaka E.; Matsumoto A.; Imai H.; Sodeyama T.; Kiyosawa K.; Furuta S.; Furuwatari C.; Ueno I.; Furihata K.; Katsuyama T.; Suzuki K.; Cao K.; Mizokami M.

Nucleotide sequence diversity in E2/NS1 gene of hepatitis C virus particles in Japanese hemophiliacs with chronic hepatitis C
pp. 45-45(1)
Authors: Toyoda H.; Fukuda Y.; Koyama Y.; Urano F.; Yamada M.; Marui A.; Katano Y.; Imada K.; Ebata M.; Kato O.; Hayakawa T.; Takamatsu J.

Serum hepatitis C virus (HCV) levels in HCV infected hemodialysis patients
pp. 45-45(1)
Authors: Manabe K.; Matsushima H.; Ohmori H.; Ohmori A.; Yoshino K.; Shiota T.; Shigei F.; Nanba T.; Shigei H.; Miyamura Y.; Okigaki T.; Endo H.; Yamada G.; Tsuji T.

Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis
pp. 46-46(1)
Authors: JH. K.; PJ. C.; MY. L.; TH. W.; DS. C.

Localization of HCV RNA in liver tissue by in situ hybridization
pp. 46-46(1)
Authors: Morimoto H.; Nomura S.; Jyohmura H.; Ikeoka N.; Fukuda K.; Nishiguchi S.; Kuroki T.; Ikura Y.; Sakurai M.

Characterization of hepatitis C virus core protein
pp. 46-46(1)
Authors: Yasui K.; Kohara K.; Kajita T.; Hasegawa A.; Okanoue T.; Kashima K.; Kohara M.

Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C
pp. 46-46(1)
Authors: Ito T.; Mukaigawa J.; Zuo J.; Hirabayashi Y.; Yasui K.; Mitamura K.

Cell transformation by transfection of hepatitis C virus genome segment encoding NS3
pp. 47-47(1)
Authors: Takegami T.; Hasumura Y.

Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection
pp. 47-47(1)
Authors: Kato N.; Nakazawa T.; Mizutani T.; Shimotohno K.

Replication of hepatitis C virus in cloned human T cell lymphotropic virus type-I infected cell line (MT-2)
pp. 47-47(1)
Authors: Mizutani T.; Kato N.; Shimotohno K.

Genetic drift in hypervariable region of viral genome in chimpanzees infected with hepatitis C virus
pp. 47-47(1)
Authors: Nakai K.; Saitou T.; Arakawa Y.; Kurata T.; Abe K.

Development and immune response to HCV-core DNA vaccine constructs
pp. 48-48(1)
Authors: Tokushige K.; Wakita T.; Wands J.

Floating density of circulating hepatitis C viral particles in patients with hepatitis C virus infection
pp. 48-48(1)
Authors: Hino K.; Fujii K.; Okazaki M.; Murakami C.; Okuda M.; Hanada H.; Okita K.

Serum levels of IL-10, s-IL-2R and s-ICAM-1 in HCV carriers
pp. 48-48(1)
Authors: Kuzushita N.; Hayashi N.; Katayama K.; Kanto T.; Kawanishi Y.; Mochizuki K.; Kasahara A.; Fusamoto H.; Kamada T.

Class II HLA geno- and haplotypes and progression of hepatitis C
pp. 48-48(1)
Authors: Kojima M.; Oonishi H.; Tsuda F.; Tanaka N.; Imawari M.; Aikawa T.

Flowcytometric analysis of complement receptor type 1 in chronic hepatitis C patients
pp. 49-49(1)
Authors: Kanto T.; Hayashi N.; Takehara T.; Katayama K.; Kato M.; Akiyama M.; Kasahara A.; Fusamoto H.; Kamada T.

Cryoglobulinemia and chronic hepatitis C virus disease among Japanese patients
pp. 49-49(1)
Authors: Kakumu S.; Aiyama T.; Yoshioka K.; Okumura A.; Takayanagi M.; Iwata K.; Yamada M.

HCV infection and expression of apoptosis-related antigen on peripheral blood lymphocytes in chronic hepatitis C
pp. 49-49(1)
Authors: Torimoto Y.; Hasebe C.; Nishimori H.; Kawashima T.; Fujimoto Y.; Mizuno M.; Kohda H.; Sekiya C.; Kohgo Y.

Analysis of HLA-DRB1 in patients infected with hepatitis C virus
pp. 49-49(1)
Authors: Miyamoto T.; Yasunami R.; Yasumaru M.; Murata H.; Sato T.; Ishigami Y.; Kanda T.; Shimizu Y.

The frequency of TH1 and TH2 in the peripheral blood mononuclear cells from patients with chronic hepatitis C.
pp. 50-50(1)
Authors: Kobayashi K.; Ishii M.; Toyota T.

High prevalence of thyroid auto-antibodies in patients with chronic hepatitis C
pp. 50-50(1)
Authors: M.J. H.; R.N. C.; S.L. T.; Y.F. L.

Epidemiological study of hepatitis C virus (HCV) transmission using phylogenetic tree construction
pp. 50-50(1)
Authors: Hara T.; Setoguchi Y.; Kajihara S.; Mizuta T.; Yamamoto K.; Inoue T.; Ohba K.; Sakai T.; Sumita I.; Mizokami M.

The epidemiological studies on HCV genotypes in the endemic area of hepatitis C virus infection where genotype III/2a is highly prevalent
pp. 50-50(1)
Authors: Yoda Y.; Ochiai M.; Kitahara Y.; Miyazaki Y.; Ainota T.; Akahane Y.; Kobayashi K.; Suzuki N.; Fujino M.A.

Nucleotide diversity of hepatitis C virus E2NS1 region and its correlation with subsequent interferon- therapy
pp. 51-51(1)
Authors: Cao K.; Suzuki K.; Orito E.; Ohba K.; Mizoguchi N.; Koide T.; Terashima H.; Nakano T.; Mizokami M.

Seroepidemiologic study of hepatitis B and C virus infection among Koreans in Korea
pp. 51-51(1)
Authors: C S.; HR S.; KY J.; WS K.; JY K.; CU L.; BO L.; TS P.; YH L.; ID O.; S K.; M R.; K K.; YO A.

Different distribution of hepatitis C virus serologically defined genotypes in east asia
pp. 51-51(1)
Authors: Mizoguchi N.; Mizokami M.; Lin H.; Chen D.; Fang Z.; SS W.; XM G.; SK Y.; BS K.; Dorjsuren D.; Kohara M.; Matsushima T.; Iino S.; Kiyosawa K.; Yano M.; Sakugawa H.

New subtypes of HCV type2 in Guinea Conakry
pp. 51-51(1)
Authors: Kouruma F.; Rapicetta M.; Ruggieri A.; Argentini C.; D'Ugo E.; Spada E.; Chionne P.; Sabbatani S.

New genotyping of hepatitis C virus and their geographical distribution
pp. 52-52(1)
Authors: Wu R.; Mizokami M.; Orito E.; Suzuki K.; Ohba K.; Mizoguchi N.; Terashima H.; Nakano T.; Cao K.; Ohno T.; Tokudome S.

Molecular evolutionary classification of hepatitis C virus based on phylogenetic trees and genetic distance
pp. 52-52(1)
Authors: Ohba K.; Mizokami M.; Orito E.; Suzuki K.; Ohno T.; Mizoguchi N.; Koide T.; Terashima H.; Nakano T.; Ikeo K.; Gojobori T.

Entire nucleotide sequence of hepatitis C virus (type 3B or Tr) isolated from a Japanese patient
pp. 52-52(1)
Authors: Chayama K.; Kobayashi M.; Tsubota A.; Suzuki Y.; Arase Y.; Koida I.; Saitoh S.; Murashima N.; Ikeda K.; Kumada H.; Kobayashi M.; Koike H.; Hashimoto M.

Hepatitis C virus infection in pediatric transfusion recipients and its natural course.
pp. 52-52(1)
Authors: Yamashita Y.; Fujisawa T.; Nakashima E.; Inoue T.; Kimura A.; Kato H.; Kage M.

Clinical investigation of children with positivity of anti-HCV and with normal liver function test
pp. 53-53(1)
Authors: Tajiri H.; Kozaiwa K.; Tada K.; Etani Y.; Sawada A.; Okada S.

Natural course of transfusion-transmitted HCV infection in childhood
pp. 53-53(1)
Authors: Kozaiwa K.; Tajiri H.; Tada K.; Etani Y.; Sawada A.; Ozaki Y.; Harada T.; Okada S.; Deguchi M.; Hosotsubo H.

Alteration of serum hepatitis C virus RNA level in children with chronic hepatitis C
pp. 53-53(1)
Authors: Kaji S.; Iitsuka T.; Nagata I.; Harada Y.; Matsuda R.; Tanaka Y.; Tanimoto K.; Hino S.; Shiraki K.

Evaluation of spontaneous remission in children with chronic hepatitis C
pp. 53-53(1)
Authors: Komatsu H.; Inui A.; Ohkawa T.; Miyagawa Y.; Ishikawa M.; Kuroki Y.; Onoue M.; Fujisawa T.

Study of perinatal HCV transmission-expression and persistence of HCV RNA in infants' peripheral blood -
pp. 54-54(1)
Authors: Moriya T.; Ohno N.; Mohri H.; Katayama K.; Sasaki F.; Yoshizawa H.

Estimation of the number of HCV carriers among healthy people
pp. 54-54(1)
Authors: Sasaki F.; Katayama K.; Moriya T.; Tanaka J.; Nagakami H.; Mizui M.; Nakanishi T.; Yoshizawa H.

Survey of incidence of HCV carrier by horizontal transmission
pp. 54-54(1)
Authors: Tanaka J.; Mizui M.; Nagakami H.; Hiraoka M.; Tamaru R.; Terada Y.; Katayama K.; Sasaki F.; Moriya T.; Yoshizawa H.

Viral genomic features of asymptomatic HCV carriers comparing with chronic hepatitis C
pp. 54-54(1)
Authors: Izumi N.; Fujisawa K.; Nakahira S.; Matsuda T.; Uchihara M.; Murakami T.; Ono K.; Noguchi O.; Miyake S.; Enomoto N.; Sato C.

The virological and histological states of anti-HCV-positive subjects with normal liver biochemical values.
pp. 55-55(1)
Authors: Shindo M.; Arai K.; Sokawa Y.; Okuno T.

Analysis of the core region of HCV genome isolated from patients with chronic hepatitis C during intervals of normal ALT concentration
pp. 55-55(1)
Authors: Arataki K.; Nakanishi T.; Ohbatake T.; Sanada E.; Nakayama J.; Katayama K.; Sasaki F.; Moriya T.; Kajiyama G.

Changes of hepatitis C-virus RNA quantity in the natural course of chronic hepatitis C and correlation with disease condition
pp. 55-55(1)
Authors: Hasebe C.; Kawashima T.; Torimoto Y.; Kohda H.; Mizuno M.; Fujimoto Y.; Nishimori H.; Yazaki Y.; Sekiya C.; Kohgo Y.

Relationship Between Hepatitis C Virus and Progression of Hepatic Lesions in Hepatitis C Diseases
pp. 55-55(1)
Authors: Matsumura H.; Moriyama M.; Suzuki K.; Arakawa Y.; Sugitani M.; Uchida T.; Suzuki K.; Shikata T.

Clinical evaluation of liver sonoelasticity by measuring internal forced low frequency vibration
pp. 56-56(1)
Authors: Sanada M.; Ebara M.; Fukuda H.; Yoshikawa M.; Sugiura N.; Ohto M.

Effect of synthetic RGD peptide on hepatic fibrosis
pp. 56-56(1)
Authors: Mizuhara Y.; Yamauchi M.; Takahashi A.; Nishikawa F.; Takagi M.; Maezawa Y.; Nakajima H.; Toda G.

Clinical evaluation of serum TIMP2 and MMP2 levels in patients with acute hepatitis
pp. 56-56(1)
Authors: Ebata M.; Fukuda Y.; Koyama Y.; Urano F.; Yamada M.; Marui A.; Katano Y.; Imada K.; Kato O.; Toyoda H.; Hayakawa T.

Plasma TIMP and TGF-1 in patients with chronic liver disease and hepatocellular carcinoma.
pp. 56-56(1)
Authors: Nishimura Y.; Murawaki Y.; Kawasaki H.

Serum fibrotic markers in patients with chronic liver disease: relationship to liver histology.
pp. 57-57(1)
Authors: Murawaki Y.; Nishimura Y.; Koda M.; Yamada S.; Kawasaki H.

Biochemical analysis of serum and hepatic 7S fragment of type IV collagen in cheonic liver disease
pp. 57-57(1)
Authors: Hosho K.; Suou T.; Yamada S.; Kawasaki H.

Evaluation of response to IFN therapy using new assay systems for serum type 4 collagen in patients with chronic hepatitis C.
pp. 57-57(1)
Authors: Saitoh S.; Shibuya A.; Takeuchi A.; Asano A.; Tsuchihashi T.; Nakazawa T.; Satoh M.; Matsumoto Y.; Murakami M.; Kokubu S.; Shibata H.; Saigenji K.

Effect of interferon alfa on serum markers for hepatic fibrosis in patients with chronic hepatitis C.
pp. 57-57(1)
Authors: Suou T.; Hosho K.; Shiota G.; Yamamoto T.; Murawaki Y.; Horie Y.; Kawasaki H.; Koda M.

Effect of interferon on hepatic fibrosis in chronic hepatitis C: analysis of hepatic extracellular matrix components using a semiquantitative scoring system (SSS)
pp. 58-58(1)
Authors: Kishida Y.; Obunai S.; Kobayashi Y.; Kashiwagi T.; Hayashi N.; Kamada T.

Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease
pp. 58-58(1)
Authors: Ikura Y.; Morimoto H.; Ikebe T.; Sakurai M.; Johmura H.; Ikeoka N.

The role of protein kinase C in lipocyte activation.
pp. 58-58(1)
Authors: Ohnuma E.; Kobayashi Y.; Murohisa G.; Suzuki F.; Kikuyama M.; Tsugiki M.; Souda K.; Kawasaki T.; Yoshimi T.

Influence of smoking habit on stellate cells in the liver of chronic hepatitis C
pp. 58-58(1)
Authors: Fujiwara M.; Besshi K.; Takemura T.; Minagawa N.; Yamada T.; Nakata R.; Yoshitsugu M.; Kato Y.; Ihori M.

Plasmin inhibitors suppress the release and activation of transforming growth factor- in rat stellate cell cultures
pp. 59-59(1)
Authors: Okuno M.; Moriwaki H.; Imai S.; Koda H.; Muto Y.; Kojima S.; Kawada N.

Myofibroblastic transformation of human fetal Ito cells
pp. 59-59(1)
Authors: Himeno H.; Enzan H.; Saibara T.; Onishi S.; Yamamoto Y.

Electron microscopical observation on stellate cells (SC) in alcoholic liver diseases (ALD) and chronic hepatitis C (CH C)
pp. 59-59(1)
Authors: Fujiwara M.; Besshi K.; Takemura T.; Minagawa N.; Yamada T.; Nakata R.; Yoshitsugu M.; Kato Y.; Ihori M.

Establishment of a human hepatocyte line from normal human liver tissue using a collagen gel sandwich culture system
pp. 59-59(1)
Authors: Kono Y.; Suyun Y.; Roberts E.A.

Expression of membrane type-matrix metalloproteinase (MT-MMP) in liver fibrosis.
pp. 60-60(1)
Authors: Takahara T.; Furui K.; Funaki J.; Itoh H.; Nakayama Y.; Satoh H.; Watanabe A.

Immunohistochemistry of type IV collagen alpha chains (1 to 6) in the liver using NC1 specific monoclonal antibodies
pp. 60-60(1)
Authors: Manabe K.; Matsushima H.; Ohmori A.; Naito I.; Sado Y.; Inoue F.; Kagawa M.; Kishiro Y.; Yamada G.; Tsuji T.

Different transcriptional mechanisms control collagen gene expression in a hepatoma cell line and mesenchymal cells
pp. 60-60(1)
Authors: Nemoto T.; Inagaki Y.; Unoura M.; Kobayashi K.

In situ hybridization of MMP-1 cDNA in small hepatocellular carcinoma
pp. 60-60(1)
Authors: Wada N.; Arai M.; Nakano M.; Saito A.; Yamamoto M.; Takasaki K.; Maruyama K.; Okazaki I.

Laminin with type IV collagen enhances malignant phenotype of hepatoma cells
pp. 61-61(1)
Authors: Torimura T.; Ueno T.; Kin M.; Inuzuka S.; Sata M.; Tanikawa K.

Late onset ornithine transcarbamylase deficiency in males
pp. 61-61(1)
Authors: Yoshino M.; Nishiyori A.; Kato H.; Kumashiro R.; Tanikawa K.

The mechanism of ammonia-induced increase in chloride ion concentration in rat cultured hippocampal neurons
pp. 61-61(1)
Authors: Irie T.; Hara M.; Yasukura T.; Inoue K.; Inagaki C.

Cerebral glucose metabolism in patients with subclinical hepatic encephalopathy using positron emission tomography
pp. 61-61(1)
Authors: Kato A.; Kaneta Y.; Obara H.; Endo R.; Iwai M.; Moriai O.; Nakadate I.; Yoshida T.; Suzuki K.; Sato S.

Experimental hepatic osteodystrophy in the rat with carbon tetrachloride-induced cirrhosis
pp. 62-62(1)
Authors: Nakano A.; Kanda T.; Shimizu Y.; Abe H.

Secondary fibrinolysis is paramount event in liver cirrhosis
pp. 62-62(1)
Authors: Takikawa Y.; Inaba H.; Katsurashima T.; Sakashita Y.; Sato S.; Iwai M.; Endo R.; Nakadate I.; Kashiwabara T.; Suzuki K.; Sato S.

EGF receptors dynamic in experimental liver cirrhosis (LC)
pp. 62-62(1)
Authors: Marotta F.; Boncinelli L.; Colombo A.; Barbi G.; D. H.C.; J. W.; Safran P.

Liver volume in patients with or without liver diseases
pp. 62-62(1)
Authors: X. Z.L.; B. S.S.; Y. H.L.; Y. N.S.; C. Y.C.; J. S.S.; H. M.T.; C. L.S.

Pathologic changes of the hepatic graft-versus-host disease (GVHD) across minor histocompatibility barriers in relation to eosinophil infiltration
pp. 63-63(1)
Authors: Nonomura A.; Kono N.; Mizukami Y.; Nakanuma Y.

Cytokine expression in the liver of primary biliary cirrhosis
pp. 63-63(1)
Authors: Nagano T.; Yamamoto K.; Ohmoto M.; Kobashi H.; Matsumoto S.; Okamoto R.; Tsuji T.

Involvement of TGF and TGF in primary biliary cirrhosis
pp. 63-63(1)
Authors: Suemori S.; Yamamoto T.; Mamata Y.; Mizuno H.; Kono M.; Suga M.; Suzuki M.; Kato Y.; Sato A.; Suzuki H.; Okabe K.; Meguro T.

Pathogenetic significance of the elevation of soluble ICAM-1 in sera of patients with primary biliary cirrhosis (PBC)
pp. 63-63(1)
Authors: Kamegaya Y.; Oda M.; Yokomori H.; Kazemoto S.; Kaneko H.; Komatsu K.; Ishii H.

Circulating intercellular adhesion molecule-1 and proinflammatory cytokines in primary biliary cirrhosis
pp. 64-64(1)
Authors: Sekiyama K.; Inoue K.; Koh I.; Yoshiba M.; Fujita R.; Thomson A.

Autoantibody against 70KD heat shock protein (HSP) in patients with autoimmune liver diseases
pp. 64-64(1)
Authors: Shingai R.; Maeda T.; Nakata S.; Saibara T.; Tomita T.; Onishi S.; Yamamoto Y.

Expression of apoptosis-related antigens in primary biliary cirrhosis
pp. 64-64(1)
Authors: Seki S.; Sakaguchi H.; Kawakita N.; Nakatani K.; Yamada T.; Masuichi H.; Kuroki T.; Kobayashi K.

Induction of nonsuppurative cholangitis by cholangiocyte immunization
pp. 64-64(1)
Authors: Ueno Y.; Ishii M.; Ludwig J.; LaRusso N.

Autophagy and endocytosis of bile duct epithelial cells in PBC.
pp. 65-65(1)
Authors: Igarashi T.; Ishii M.; Yamamoto T.; Yamada S.; Kobayashi K.; Toyota T.

Serum apolipoprotein E concentration is elevated in primary biliary cirrhosis
pp. 65-65(1)
Authors: Nakamura A.; Yamazaki K.; Abe S.; Shimotono H.; Abe K.; Nakadate I.; Suzuki K.; Sato S.

Study on the case of autoimmune cholangiopathy in our facility.
pp. 65-65(1)
Authors: Kang J.-H.; Tsuji K.; Horata K.; Yanagida K.; Kitazawa S.; Sato K.; Watanabe S.; Matsui M.; Kitagawa T.; Maekubo H.

Autoantibodies against nuclear envelope in patients with primary billiary cirrhosis
pp. 65-65(1)
Authors: Shibata M.; Kawaguchi N.; Miyakawa H.; Abe K.; Kikuchi K.; Kako M.; Shibuya A.; Oka Y.; Miyachi K.; Ueno Y.; Onozuka Y.; Terauchi K.

Prevalence and significance of anti-centromere antibody(ACA) in PBC
pp. 66-66(1)
Authors: Abe K.; Miyakawa H.; Kikuchi K.; Shibata M.; Shibuya A.; Oka Y.; Onozuka Y.; Kawaguchi N.; Miyachi K.; Ueno Y.; Kako M.

Analysis of anti-PDC-E2-producing B cell clones in the peripheral blood of a patient with primary biliary cirrhosis
pp. 66-66(1)
Authors: Fukushima N.; Nakamura M.; Hayashida K.; Matsui M.; Ishibashi H.; Niho Y.; Ikematsu H.

New anti-M2 antibody assay system for the diagnosis of primary biliary cirrhosis
pp. 66-66(1)
Authors: Onozuka Y.; Kawaguchi N.; Miyakawa H.; Abe K.; Kikuchi K.; Kako M.; Shibuya A.; Oka Y.; Miyachi K.; Ueno Y.; Shibata M.

Significance of IgM-class anti-PDH in PBC
pp. 66-66(1)
Authors: Miyakawa H.; Abe K.; Kikuchi K.; Shibata M.; Shibuya A.; Oka Y.; Onozuka Y.; Kawaguchi N.; Miyachi K.; Ueno Y.; Kako M.

PBC-like lesion is induced by immunization with recombinant PDC-E2/BCKD-E2 hybrid molecule and lipopolysaccharide injection in neonatally thymectomized mice.
pp. 67-67(1)
Authors: Masanaga T.; Watanabe Y.; Leung P.S.C.; Kamiyasu M.; Sanada E.; Myozaki M.; Nakanishi T.; Kajiyama G.; Gershwin M.E.

Identification of immunodominant T cell epitopes of pyruvate dehydrogenase complexes in primary biliary cirrhosis
pp. 67-67(1)
Authors: Shimoda S.; Ichiki Y.; Nakamura M.; Hayashida K.; Ishibashi H.; Niho Y.

Histopathological Re-evaluation of Interlobular Bile Duct Damage in Patients with Autoimmune Hepatitis (AIH) in Japan
pp. 67-67(1)
Authors: Takahashi Y.; Maeyama S.; Koike J.; Kishi M.; Aida Y.; Yoshida H.; Takakuwa T.; Uchikoshi T.

Increment of V4-positive cells in liver of neonatally thymectomized A/J mice and experimental hepatitis induced by propionibacterium acnes and lipopolysaccharide
pp. 67-67(1)
Authors: Sanada E.; Watanabe Y.; Kamiyasu M.; Naiki M.; Myozaki M.; Kitamoto M.; Nakanishi T.; Kajiyama G.

T-cell receptor V chain usage of liver infiltrating lymphocyte (LIL) in autoimmune hepatitis (AIH)
pp. 68-68(1)
Authors: Kuramoto A.; Takahasi H.; Karasawa T.; Enomoto Y.; Atarashi T.; Okuda J.; Koike K.; Fukata H.; Shimada N.; Kuniyasu H.; Ohtani S.; Hayashi A.; Kawabe T.; Shimizu Y.; Aizawa Y.; Zeniya M.; Toda G.

Measurement of self-reactive B lymphocytes in peripheral blood of patients with autoimmune liver disease
pp. 68-68(1)
Author: Ishimaru H.

Serum soluble CD4 and soluble CD8 levels in autoimmune liver diseases
pp. 68-68(1)
Authors: Hayashida K.; Takasaki S.; Morita C.; Mukai T.; Ishibashi H.; Niho Y.

Histopathological study of noncancerous liver tissue in alcoholic liver disease complicated by hepatocellular carcinoma
pp. 68-68(1)
Authors: Taniai M.; Hashimoto E.; Aoka K.; Ishiguro N.; Saito A.; Hayashi N.; Takasaki K.

Influences of chronic ethanol feeding on kupffer cell-induced mitochondrial dysfunction in hepatoma cells
pp. 69-69(1)
Authors: Kurose I.; Kato S.; Ebinuma H.; Higuchi H.; Saito H.; Miura S.; Ishii H.

Different CYP2E1 genotypes and alcoholic liver disease.
pp. 69-69(1)
Authors: Tsutsumi M.; Ueshima Y.; Kawahara H.; Takase S.; Takada A.

Ethanol oxidation activity by human hepatic cytochrome P450 1A2
pp. 69-69(1)
Authors: Asai H.; Yamada T.; Kunitoh S.; Yamashita T.; Tanaka T.; Nishiguchi S.; Kuroki T.; Imaoka S.; Monna T.; Kobayashi K.; Funae Y.

Expression of different types of -glutamyl transpeptidase mRNA in alcohol-fed rat liver
pp. 69-69(1)
Authors: Sakamoto K.; Yamauchi M.; Maezawa Y.; Searashi Y.; Takagi M.; Kawashima O.; Takahashi A.; Satoh S.; Nishikawa F.; Mizuhara Y.; Hirakawa J.; Nakajima H.; Toda G.

Effect of chronic ethanol treatment on signal transduction systems in hepatocytes - action of protein kinase A
pp. 70-70(1)
Authors: Nomura T.; Tsukada K.; Hoshino M.; Higashi K.; Saso K.; Akita M.; Isobe T.; Takahashi Y.; Nakao H.; Hayakawa T.; Takeuchi T.

Okadaic acid, a protein phosphatase inhibitor, enhances ethanol-induced desensitization of receptor-mediated phospholipase C activation in isolated rat hepatocytes
pp. 70-70(1)
Authors: Higashi K.; Tsukada I.; Hoshino M.; Nomura T.; Saso K.; Akita M.; Isobe T.; Takahashi Y.; Nakao H.; Hayakawa T.; Takeuchi T.

Hydrogen peroxide mediates ethanol-induced mitochondrial dysfunction in rat hepatocytes
pp. 70-70(1)
Authors: Tomita K.; Kurose I.; Higuchi H.; Kamegaya Y.; Horie Y.; Kato S.; Miura S.; Ishii H.

Influence of dietary zinc on hepatocytotoxicity and lipid peroxidation in rats fed a liquid diet with ethanol and carbonyl iron: comparison beteen low zinc diet and standard zinc diet
pp. 70-70(1)
Authors: Irie M.; Sohda T.; Takeyama Y.; Kamimura S.; Okumura M.

Hepatocytotic clearance of lipopolysaccharide in chronically alcohol-fed rats.
pp. 71-71(1)
Authors: Mimura Y.; Sakisaka S.; Kumashiro R.; Sata M.; Tanikawa K.

Long-term ethanol treatment affects IL-8 production of cultured chang liver cells.
pp. 71-71(1)
Authors: Ohira H.; Kuroda M.; Takagi T.; Miyata M.; Nishimaki T.; Kasukawa R.

Effect of vitamin E deficiency on inhibition of liver regeneration by long-term alcohol administration
pp. 71-71(1)
Authors: Tanaka T.; Goto Y.; Imano M.; Asai H.; Yamada T.; Kawai S.; Yamashita T.; Monna T.; Nishiguchi S.; Kuroki T.; Otani S.

Study on effect of EGF on hepatic tissue PGE2 in rats with acute hepatic failure
pp. 71-71(1)
Authors: Komaba M.; Kamoshita H.; Kuga K.; Arai T.; Toshima K.; Uematsu M.; Imai F.; Toda G.

Anticoagulant and antibacterial activity of type II phospholipase A2: possible host-defensive action against fulminant hepatic failure
pp. 72-72(1)
Authors: Inada M.; Kawata S.; Matsuzawa Y.; Weiss J.

Evidence of active release of asialoglycoprotein receptor from HepG2 cells
pp. 72-72(1)
Authors: Hisai H.; Kato J.; Nakajima M.; Ohkubo S.; Yago H.; Kohgo Y.; Niitsu Y.

Fibrinolysis and fibrinogenolysis in acute hepatic failure
pp. 72-72(1)
Authors: Inaba H.; Takikawa Y.; Sakashita Y.; Sato S.; Iwai M.; Endo R.; Nakadate I.; Kashiwabara T.; Suzuki K.; Sato S.

Changes in serum TNF-, soluble TNF receptor and ICAM-1 levels in patients with acute viral hepatitis
pp. 72-72(1)
Authors: Abe K.; Nakadate I.; Iwai M.; Endo R.; Shimotono H.; Takikawa Y.; Yamazaki K.; Kato A.; Suzuki K.; Sato S.

Changes in serum type IV collagen-degrading metalloproteinases and tissue inhibitor of metalloproteinases in patients with acute liver failure
pp. 73-73(1)
Authors: Endo R.; Suzuki K.; Sakashita Y.; Inaba H.; Iwai M.; Moriai O.; Nakadate I.; Takikawa Y.; Miura Y.; Kato A.; Yoshida T.; Sato S.

Metabolic fate of endotoxin in acute hepatic failure of rats induced by D-galactosamine: role of Kupffer cell and splenic macrophage
pp. 73-73(1)
Authors: Hoppou K.; Kitano H.; Fukui H.; Kikuchi E.; Matsumoto M.; Kikkawa M.; Nagamoto K.; Tsujita S.; Tsujii T.; Okamoto Y.

Induction of peripheral-type benzodiazepine receptors in mouse brain following thioacetamide-induced acute liver failure
pp. 73-73(1)
Authors: Kadota Y.; Naitoh Y.; Miyazaki H.; Kuno K.; Ueno Y.; Okajima A.; Inoue K.

Effect of plasmapheresis on removal of circulating endotoxin and cytokine in severe liver diseases
pp. 73-73(1)
Authors: Iwai H.; Nagaki M.; Naito T.; Ishiki Y.; Murakami N.; Sugihara J.; Ohnishi H.; Moriwaki H.; Muto Y.

Development of a bioartificial liver using hepatocytes entrapped in EHS gel
pp. 74-74(1)
Authors: Noda N.; Nagaki M.; Sugiyama A.; Naito T.; Ohnishi H.; Moriwaki H.; Muto Y.

Changes of gap-junction in carbon tetrachloride-induced liver injury in rats
pp. 74-74(1)
Authors: Watanabe Y.; Kito K.; Iseki S.; Takahashi H.; Kimura S.; Nakata Y.; Iwai M.; Sato M.

Effect of the EGF-receptor-inhibitor on primary cultured hepatocytes isolated from transgenic mice of transforming growth factor
pp. 74-74(1)
Authors: Ichikawa T.; Takehara K.; Takagi H.; Arai H.; Shimoda T.; Matsumoto T.; Saito S.; Yuasa K.; Arai T.; Nagamine T.; Yamada S.; Mori M.

An experimental sturdy on administration of 5FU into portal vein and residual hepatic regeneration after partial hepatectomy
pp. 74-74(1)
Authors: Hasegawa K.; Komori Y.; Wakayama A.; Okamoto K.; Soga R.; Torii K.; Yasuda Y.; Kimura A.; Esaki T.; Sugioka A.; Sugenoya H.; Hasumi A.

Relationship between inhibitory effect of activin A on hepatocyte proliferation and appearance of connexin gap junctional protein
pp. 75-75(1)
Authors: Mine T.; Yasuda H.; Kataoka A.; Tajima A.; Nagasawa J.; Kushima R.; Fujita T.

Fas antigen was strongly expressed on the cell surface of the hepatocytes in fulminant hepatitis patients
pp. 75-75(1)
Authors: Ryo K.; Kamogawa Y.; Ikeda I.; Kimura T.; Nishikawa M.; Sekiya H.; Haruta I.; Kato T.; Furukawa T.; Yamauchi K.; Hayashi N.

Apoptosis in rat liver after administration of hepatocyte growth factor
pp. 75-75(1)
Authors: Nagoshi S.; Suda J.; Fujiwara K.

Role of liver resident NK cells in endotoxin-induced liver apoptosis.
pp. 75-75(1)
Authors: Tsutsui H.; Matsui K.; Nakanishi K.; Higashino K.; Miyazawa Y.; Kaneda K.

Apoptosis in liver of the autopsy cases with acute hepatic failure
pp. 76-76(1)
Authors: Yamada T.; Nakayama T.; Saio M.; Takami T.; Watanabe Y.; Murakami N.; Nakamura N.; Shidoji Y.

Involvement of apoptosis in the process of hepatitis and hepatoma of LEC rats by apoptosis-specific antibody
pp. 76-76(1)
Authors: Sugiyama T.; Yasui O.; Miura N.; Terada K.; Koyama K.

Kupffer cells may play a role in apoptosis of hepatocytes in allograft rejection after rat liver transplantation
pp. 76-76(1)
Authors: Tanaka Y.; Teramoto K.; Kusano F.; Tang L.; Ono K.; Goto M.; Marumo F.; Iwai T.; Sato C.

The study of apoptosis with chronic hepatitis C before and after interferon therapy.
pp. 76-76(1)
Authors: S. K.; G. K.; Sasaki K.; Hamada K.; Aoki K.; C. S.; J. K.; Asano J.; M. R.; H. K.; Araki H.; Hayashi Y.

Hepatocyte growth-promoting factor (pHGF)induce apoptosis in proliferating human hepatocellualar carcinoma cells in vitro
pp. 77-77(1)
Authors: Wei Y.; Jin E.; Zhao T.; Cao W.; Liou D.; Zhang Y.; Kong X.; Niu J.

Hepatocyte growth factor prevents the onset and progress of dimethylnitrosamine-induced liver cirrhosis in rats
pp. 77-77(1)
Authors: Matsuda Y.; Matsumoto K.; Ichida T.; Asakura H.; Nakamura T.

Continuous HGF supply prevents CCl₄-induced acute liver injury in rats
pp. 77-77(1)
Authors: Kaido T.; Tanaka J.; Funaki N.; Kasamatsu T.; Seto S.; Imamura M.; Yamaoka S.

Immunohistochemical studies on the expression of HGF and HGF receptor in carbon tetrachloride-treated monkeys
pp. 77-77(1)
Authors: Matsushita R.; Ishinoda Y.; Etoh T.; Tomokiyo Y.; Ochiai T.; Kawano T.; Hirono S.; Hayashi K.; Maruyama T.; Tsubouchi H.

Expression of hepatocyte growth factor (HGF) and HGF activator in carbon tetrachloride-induced acute hepatic injury
pp. 78-78(1)
Authors: Ishinoda Y.; Matsushita R.; Etoh T.; Hirono S.; Komura K.; Kitamura T.; Hayashi K.; Maruyama T.; Miyazawa K.; Kitamura N.; Tsubouchi H.

The role of bFGF in hepatic regeneration after ischemia reperfusion injury in rats
pp. 78-78(1)
Authors: Kawachi S.; Shimazu M.; Wakabayashi G.; Shirasugi N.; Kumamoto Y.; Karahashi T.; Yoshida M.; Kitajima M.

Hepatocyte proliferation induced in rats by lead nitrate is suppressed by several tumor necrosis factor- inhibitors
pp. 78-78(1)
Authors: Kubo Y.; Yasunaga M.; Tanigawa K.; Tamura O.; Wasaki S.; Terai S.; Yasunaga M.; Sakaida I.; Nakamura T.; Okita K.

Role of heparin-binding EGF-like growth factor (HB-EGF) in rat liver regeneration: cell specificity of HB-EGF gene expression and induction of HGF and TGF- gene expression by HB-EGF
pp. 78-78(1)
Authors: Kiso S.; Kawata S.; Tamura S.; Ito N.; Tsushima H.; Oshikawa O.; Higashiyama S.; Taniguchi N.; Matsuzawa Y.

Interleukin-6 induces proliferation of rat hepatocytes in vivo
pp. 79-79(1)
Authors: Ohira H.; Miyata M.; Kuroda M.; Takagi T.; Nishimaki T.; Kasukawa R.

The effect of recombinant human hepatocyte growth factor on the functions of rat hepatocytes in primary culture
pp. 79-79(1)
Authors: Kamachi H.; Matshsita M.; Takahashi M.; Nishikawa M.; Taguchi K.; Koike M.; Kon H.; Uchino J.

Inhibition by ethanol of HGF-induced DNA synthesis and Ca²⁺ mobilization in rat hepatocytes.
pp. 79-79(1)
Authors: Saso K.; Tsukada K.; Hoshino M.; Higashi K.; Nomura T.; Akita M.; Isobe T.; Takahashi Y.; Nakao H.; Hayakawa T.; Takeuchi T.

Cellular polarity in undiferentiated hepatocyte doublets during liver regeneration
pp. 79-79(1)
Authors: Yamada T.; Kitamura T.; Hirose M.; Enomoto N.; Yumoto A.; Suzuki S.; Watanabe S.; Kitami N.; Sato N.

A study of cytoskeltons of the hepatocytes in primary culture as a model for the introduction of hepatocytes into a cell cycle for liver regeneration
pp. 80-80(1)
Authors: Furune T.; Delamou A.D.; Mito M.

Effect of extracellular matrix on Ca²⁺ oscillations.
pp. 80-80(1)
Authors: Kitamura T.; Watanabe S.; Hirose M.; Yamada T.; Enomoto N.; Yumoto A.; Suzuki S.; Kitami N.; Sato N.

Hepatic injury and regeneration after transient ischemia of rat liver
pp. 80-80(1)
Authors: Akashi T.; Sato Y.; Sasaki N.; Kusano T.; Koyama K.

Participation of intestine-derived cytokines in liver regeneration following liver resection
pp. 80-80(1)
Authors: Higashiguchi T.; Ito A.; Kawarada Y.

Role of macrophages in regeneration of the liver
pp. 81-81(1)
Authors: Hongo S.; Ohmura K.; Arima T.; Fukuchi T.; Nagura T.; Kiriyama H.; Takada H.; Matsumoto K.; Shiratori Y.

Different sugar chains of AFP produced in acute hepatitis and chronic liver diseases
pp. 81-81(1)
Authors: Taketa K.; Liu M.; Yamamoto H.; Ogata M.; Ikeda S.; Ohmori A.; Akamatsu K.; Sekiya C.; Taga H.

Growth-promoting activity of TIMP-1 for hepatoma cells
pp. 81-81(1)
Authors: Katano Y.; Fukuda Y.; Koyama Y.; Nakano I.; Urano F.; Yamada M.; Marui A.; Imada K.; Kato O.; Ebata M.; Toyoda H.; Hayakawa T.; Yamashita K.; Iwata K.; Hayakawa T.

Effect of central tyhrotropin-releasing hormone (TRH) on hepatic proliferation
pp. 81-81(1)
Authors: Yoneda M.; Yokohama S.; Tamori K.; Sato Y.; Nakamura K.; Kimura A.; Fujita M.; Baba K.; Saitoh H.; Akiyama K.; Makino I.

Putrescine as a comitogen in cultured rat hepatocytes and its action site(s)
pp. 82-82(1)
Authors: Nagoshi S.; Suda J.; Fujiwara K.

Variation in liver fatty acid binding protein (L-FABP) and peroxisomal -oxidation (PO) in partially hepatectomized rats is dependent on PPAR.
pp. 82-82(1)
Authors: de Foronda M.; Cereceda R.M.; Guijarro M.C.; Diaz-Gil J.J.

Transfection of N-acetylglucosaminyltransferase-III gene suppresses expression of hepatitis B virus gene in a human hepatoma cell line, HB611.
pp. 82-82(1)
Authors: Miyoshi E.; Hayashi N.; Ihara Y.; Nishikawa A.; Fusamoto H.; Kamada T.; Taniguchi N.

Effect of HBx gene on response to growth inhibition by TGF-
pp. 82-82(1)
Authors: Tamura S.; Kawata S.; Oshikawa O.; Ito N.; Tsushima H.; Kiso S.; Matsuzawa Y.

Human hepatitis B virus enhancer 1 is responsive to human interleukin-6
pp. 83-83(1)
Authors: Ohno H.; Kaneko S.; Masashi U.; Kobayashi K.; Matsushima K.; Murakami S.

Hepatic gene therapy: relationship between gene delivery, expression and aging
pp. 83-83(1)
Authors: Kaji K.; Kaneko S.; Koura T.; Unoura M.; Kobayashi K.

Hepatic gene therapy: gene delivery and expression in cirrhotic liver
pp. 83-83(1)
Authors: Koura T.; Kaneko S.; Kaji K.; Unoura M.; Kobayashi K.

Cell-specific and non-cell-specific enhancer activity in a far upstream region of the human -fetoprotein gene
pp. 83-83(1)
Authors: Nakabayashi H.; Suzuki H.; Tamaoki T.

Alterlation of hepatic O6-methyl-guanine DNA methyltransferase levels in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
pp. 84-84(1)
Authors: Noguchi O.; Tajiri K.; Kamiyama T.; Liu J.; Miyakawa H.; Marumo F.; Sato C.

Activation of phosphatidylinositol 3-kinase in hepatocyte growth and hepatocellular transformation
pp. 84-84(1)
Authors: Sasaki Y.; Wands J.R.; Hayashi N.; Horimoto M.; Wada S.; Itoh Y.; Fusamoto H.; Kamada T.

Role of nitric oxide in endotoxin-induced liver injury
pp. 84-84(1)
Authors: Takemura S.; Minamiyama Y.; Yamamasu S.; Kubo S.; Hirohashi K.; Kinoshita H.; Inoue M.

Effect of tissue plasminogen activator (t-PA) administration on dimethylnitrosamine(DMN)-induced liver injury in rats.
pp. 84-84(1)
Authors: Mamata Y.; Kato Y.; Mizuno H.; Tominaga T.; Suga M.; Suemori S.; Suzuki M.; Suzuki H.; Meguro T.; Okuhara Z.; Shinagawa T.; Okabe K.

Experimental study on remnant liver failure after extensive hepatectomy using an isolated Kupffer cells and hepatocyte co-culture system, with special reference to TXA2 and PGI2
pp. 85-85(1)
Authors: Tanigawa K.; Iwata M.; Yokoi H.; Noguchi T.; Kawarada Y.

Change of intracellular calcium concentration of hepatocytes during experimental endotoxemia in rats
pp. 85-85(1)
Authors: Akimoto H.; Okajima K.; Isozaki H.; Hara H.; Kobayashi M.; Fujii K.; Nomura E.; Sasaki S.; Nakagaki I.

The role of intracellular calcium on a release of superoxide anion from Kupffer cells and the efficacy of PGE₁
pp. 85-85(1)
Authors: Kurosawa H.; Nakano A.; Natori S.; Fujii Y.; Endo I.; Kunisaki C.; Sekido H.; Shimada H.

Analysis of pathophysiology after hepatic resection combined with pancreatectomy-long-lasting catabolism following 50% hepatic resection combined with 70% pancreatectomy in rats
pp. 85-85(1)
Authors: Okuda J.; Itakura J.; Yamamoto M.; Karikomi K.; Fujii H.; Miura K.; Matsumoto Y.

Cytoprotective effects of dibutyryl cyclic AMP (DBc-AMP) on hypoxia/reoxygenation injury of HepG2 cell line
pp. 86-86(1)
Authors: Ayukawa K.; Sakai H.; Nawata H.

Cytoprotective effect of hepatocyte growth factor (HGF) for acute liver injury in HGF transgenic mice
pp. 86-86(1)
Authors: Okano J.; Shiota G.; Kawasaki H.

The mechanism of the primary ischemia/reoxygenation injury from the aspect of iron chelation
pp. 86-86(1)
Authors: Ozaki M.; Fuchinoue S.; Teraoka S.; Ota K.

Interaction between hepatocyte and Kupffer cell: from the viewpoint of biliary excretion of lipopolysaccharide in the liver
pp. 86-86(1)
Authors: Hori Y.; Takeyama Y.; Ueda T.; Nishikawa J.; Ueno N.; Yamamoto M.; Saitoh Y.

Enhanced liver injury in acatalasemic mice following exposure to carbon tetrachloride
pp. 87-87(1)
Authors: Wang D.; Ishii K.; Zhen L.; Taketa K.

Mechanism of dyslipidemia induced by interferon treatment of chronic hepatitis C
pp. 87-87(1)
Authors: Wakashima M.; Katsuragawa K.; Kaneko K.; Shimazu N.; Suga S.; Kinoshita M.; Miyake K.; Teramoto T.; Yamanaka M.

Characterization of Energy Metabolism in Patients with Acute Hepatic Failure by Indirect Calorimetry
pp. 87-87(1)
Authors: Tajika M.; Kato M.; Miwa Y.; Hiraoka T.; Sugihara J.; Moriwaki H.; Muto Y.

Effect of high sucrose diet on apolipoprotein gene expression in fatty liver with obesity
pp. 87-87(1)
Authors: Inui Y.; Kawata S.; Keno Y.; Fukuda K.; Maeda Y.; Nakamura T.; Tokunaga K.; Matsuzawa Y.

Iron depletion by feeding with iron-deficient diet prevents the development of liver cancer in LEC rats
pp. 88-88(1)
Authors: Kobune M.; Kato J.; Sugawara N.; Katsuki S.; Kohgo Y.; Niitsu Y.

Effects of tryptophan metabolites on liver injury
pp. 88-88(1)
Authors: Uesugi K.; Nagamura Y.; Ito M.; Ishiguro I.; Saitoh K.; Noma A.

Effect of interferon on the synthesis of lipids and apolipoproteins in HEPG2 cells.
pp. 88-88(1)
Authors: Shimazu N.; Wakashima M.; Nakata K.; Kaneko K.; Kinoshita M.; Miyake K.; Teramoto T.; Yamanaka M.

Regulation of the valine catabolism in human liver: comparison between normal liver and cirrhotic liver
pp. 88-88(1)
Authors: Taniguchi K.; Nonami T.; Nakao A.; Harada A.; Kurokawa T.; Shimomura Y.; Takagi H.

Effect of glyconeogenic amino acids on liver energy and polyamine levels in rats with acute liver failuret.
pp. 89-89(1)
Authors: Gotoh T.; Kuroda T.; Otani S.; Nishiguchi S.; Kuroki T.; Kobayashi K.

Glucose intolerance in patients with chronic liver diseases -- analysis of insulin secretion and sensitivity
pp. 89-89(1)
Authors: Kanda T.; Ishigami Y.; Satoh T.; Shimotani M.; Yasumaru M.; Murata H.; Miyamoto T.; Shimizu Y.

Regulation of albumin gene expression in carbon tetrachloride-induced liver cell injury
pp. 89-89(1)
Authors: Obara H.; Kato A.; Suzuki K.; Kuwahata M.; Oka T.; Natori Y.; Sato S.

Tauroursodeoxycholate (TUDC) suppresses a stimulatory effect of dbcAMP on vasopressin (VP)-induced changes in bile flow in isolated perfused rat liver (IPRL).
pp. 89-89(1)
Authors: Hayakawa T.; Higashi K.; Yamada H.; Yamada T.; Mizuno K.; Nakazawa T.; Inagaki T.; Uchida A.; Kamiya Y.; Hoshino M.; Miyaji M.; Takeuchi T.

Papaverine(PA) suppresses vasopressin(VP)-induced phospholipase C activation in the rat liver
pp. 90-90(1)
Authors: Yamada H.; Hayakawa T.; Higashi K.; Yamada T.; Inagaki T.; Nakazawa T.; Uchida A.; Kamiya Y.; Nomura T.; Oohara H.; Iida M.; Hoshino M.; Miyaji M.; Takeuchi T.

Nuclear translocation of the glucocorticoid receptor by ursodeoxycholic acid
pp. 90-90(1)
Authors: Miura T.; Tanaka H.; Hirano F.; Inaba M.; Makino Y.; Sato Y.; Makino I.

Bezafibrate and its mechanism of choleresis
pp. 90-90(1)
Authors: Sezai S.; Yamamoto Y.; Sakurabayashi S.; Hirano M.; Oka H.; Kamisaka K.

Evaluation of energy metabolism related to bile formation in isolated perfused rat liver using 31P-NMR spectroscopy
pp. 90-90(1)
Authors: Nakashima T.; Sakai M.; Nakajima T.; Inaba K.; Sakamoto Y.; Shima T.; Iwai M.; Okanoue T.; Kashima K.

Epimerization of isoursodeoxycholic acid to ursodeoxycholic acid in the rat liver.
pp. 91-91(1)
Authors: Nakamura K.; Yokohama S.; Tamori K.; Sato Y.; Fujita M.; Kimura A.; Baba K.; Hasegawa T.; Saito H.; Yoneda M.; Makino I.

Effects of ursodeoxycholate (UDC) and its conjugates on biliary glutathione excretion
pp. 91-91(1)
Authors: Kitaura K.; Takikawa H.; Sano N.; Yamazaki R.; Fukumura S.; Wako Y.; Fujiyoshi M.; Kuyama Y.; Miyake K.; Yamanaka M.

Ursodeoxycholic acid (UDCA) increases biliary secretion of glutathione (GSH)
pp. 91-91(1)
Authors: Yoshida H.; Ohmura K.; Onuki K.; Okano K.

Enhancing effects of ursodeoxycholic acid (UDCA) on glutathione S-transferase (GST) enzyme activities and isozyme concentrations in mouse liver cytosol.
pp. 91-91(1)
Authors: Kanai S.; Kitani K.

A kinetic analysis of reduced glutathione (GSH) transport in rat basolateral liver plasma membrane vesicles (bLPM).
pp. 92-92(1)
Authors: Tsukahara K.; Yoshida H.; Shiratori Y.; Okano K.; Omata M.

Genetic defect of Crigler-Najjar syndrome type II in a Japanese patient
pp. 92-92(1)
Authors: Yamamoto K.; Sato H.; Soeda Y.; Fukano M.; Nagano M.; Okumura Y.; Okuma K.; Adachi Y.; Fujiyama Y.; Bamba T.; Doida Y.

The mechanisms of biliary excretion of estradiol-17-glucuronide (E₂17G).
pp. 92-92(1)
Authors: Yamazaki R.; Takikawa H.; Sano N.; Takamori Y.; Fukumura S.; Kitaura K.; Nishikawa K.; Yokote M.; Miyake K.; Yamanaka M.

Possible causes leading to conjugated hyperbilirubinemia in mutant (EHBR) rats.
pp. 92-92(1)
Authors: Uesawa Y.; Ikegami Y.; Sano K.; Uesugi T.; Kamisaka K.

The effect of ethynyl estradiol treatment (EE) on the lateral diffusion constants of proteins and lipids in plasma membranes of rat hepatocytes.
pp. 93-93(1)
Authors: Kitani K.; Zs.-Nagy I.

Biliary excretion of various compounds in ehyinylestradiol (EE)-induced cholestasis
pp. 93-93(1)
Authors: Takamori Y.; Takikawa H.; Sano N.; Yamazaki R.; Kitaura K.; Nakaki M.; Yokote M.; Kuyama Y.; Miyake K.; Yamanaka M.

Increased sinusoidal efflux and decreased excretion of bile acids by the inhibition of binding to the cytosol Y' bile acid binders (BAB).
pp. 93-93(1)
Authors: Takikawa H.; Sugiyama Y.; Fernandez-Checa J.C.; Kaplowitz N.; Yamanaka M.

Factors affecting subselection of biliary lecithin secretion: relation to ''uncoupling phenomenon''
pp. 93-93(1)
Authors: Tazuma S.; Horikawa K.; Miyake H.; Kajiyama G.; Miura H.

Sequential Changes of Bile Contents in Patients with Obstructive Jaundice from Different Etiologies -- bile from drainage catheter
pp. 94-94(1)
Authors: Chiung-Yu C.; Shu-Chu S.; Wu-Chou S.; Kuo-Kuan C.; Xi-Zhang L.

Simultaneous determination of plasma mevalonate (MVL) and 7-hydroxy-4-cholesten-3-one (C4) levels for monitoring biliary cholesterol supersaturation in hyperlipoproteinemia (HLP)
pp. 94-94(1)
Authors: Shoda J.; He B.-F.; Ikegami T.; Kano M.; Abei M.; Matsuzaki Y.; Tanaka N.; Osuga T.

Pathgenesis of calcified gallstone--CaCO₃ supersaturation of gallbladder bile and its relationship with mucus hypersecretion.
pp. 94-94(1)
Authors: Abei M.; Tanaka N.; Shoda J.; Matsuzaki Y.; Osuga T.; Tomida S.; Yamaguchi T.

Regulation of biliary lipid secretion by bile salt hydrophobicity: relation to degree of hydrophobic-hydrophilic balance of lecithin species
pp. 94-94(1)
Authors: Tazuma S.; Miura H.; Horikawa K.; Hirano N.; Hattori Y.; Tsuchimoto D.; Ochi H.; Teramen K.; Aihara N.; Ohya T.; Kajiyama G.; Miyake H.

Serial cytotoxicities of various bile acids to cultured rat hepatocytes
pp. 95-95(1)
Authors: Nagai H.; Hata S.; Ishii K.; Okajima T.; Hatori T.; Sumino Y.; Sugimoto M.

Studies on the calcium metabolism of hormone-induced bile flow and the pharmacokinetics of the bile salts in the perfused liver of normal and cholestatic rats
pp. 95-95(1)
Author: Hamada Y.

Effects of tauroursodeoxycholic acid (TUDCA) on ischemia-reperfusion injury of rat livers
pp. 95-95(1)
Authors: Ono T.; Nagasue N.; Kohno H.; Uchida M.; Nakamura T.

Effect of administration of autologous bile to obstructive jaundice patients
pp. 95-95(1)
Authors: Ito A.; Higashiguchi T.; Naganuma T.; Taoka H.; Kawarada Y.

Neutrophil-mediated sinusoidal cell injury after extended hepatectomy in cholestatic rats followed by external drainage
pp. 96-96(1)
Authors: Ohtsuka M.; Miyazaki M.; Itoh H.; Kaiho T.; Ambiru S.; Togawa A.; Sasada K.; Shiobara M.; Shimizu Y.; Yoshioka S.; Yoshidome H.; Omoto H.; Katoh A.; Nakamura S.; Okuno A.; Nukui Y.; Nozawa S.; Yoshitomi H.; Nakajima N.; Kondo Y.

Effect of bile acids on phagocytic activity on kupfer cell
pp. 96-96(1)
Authors: Funaoka M.; Komatsu M.; Kuramitsu T.; Kato J.; Ono T.; Hoshino T.; Ishii T.; Toyoshima I.; Masamune O.

Interaction of the microtubule cytoskeleton with endocytic vesicles and cytoplasmic dynein in cultured rat hepatocytes
pp. 96-96(1)
Authors: Oda H.; Stockert R.J.; Novikoff P.M.; Satir P.; Kuroki S.; Chijiiwa K.; Tanaka M.; Wolkoff A.W.

Quantitative evaluation of the arterial hemodynamics of well-differentiated hepatocellular carcinoma by enhanced ultrasono-graphy
pp. 96-96(1)
Authors: Tohara K.; Ohara J.; Tanaka M.; Hatono N.; Ueki T.; Nakabayashi S.; Yao T.; Miyajima Y.; Sakaguchi S.; Okumura M.

A study of dynamic contrast-enhanced ultrasonography for detection of small space-occupying lesions of the liver
pp. 97-97(1)
Authors: Shimada S.; Nakano S.; Takeda I.; Kumada T.; Sugiyama K.; Osada T.; Kiriyama S.; Takahashi M.; Samori T.; Numaguchi Y.; Tomita S.

Usefulness of laparoscopic ultrasonography for diagnosis of hepatocellular carcinoma
pp. 97-97(1)
Authors: Nakazawa Y.; Kawamoto C.; Ido K.; Isoda N.; Suzuki T.; Nagamine N.; Ioka T.; Hozumi M.; Hirasawa T.; Kimura K.

Utility of carbon dioxide-enhanced ultrasonography for detection of viable lesions in treated hepatocellular carcinoma and to assist additional percutaneous ethanol injection therapy
pp. 97-97(1)
Authors: Goto T.; Siwa T.; Tochikubo O.; Ishii M.

Clinical application of a neural network to analyze parenchymal echo patterns of liver cirrhosis and usefulness for a predictive factor of hepatocellular carcinoma
pp. 97-97(1)
Authors: Fukuda H.; Ebara M.; Okabe S.; Koujima Y.; Sanada M.; Yoshikawa M.; Sugiura N.; Ohto M.; Kondo F.; Kondo Y.; Yoshino S.; Kobayashi A.

Early evaluation of the effect of non-surgical treatment for hepatocellular carcinoma(HCC) using color doppler ultrasonography and dynamic MRI
pp. 98-98(1)
Authors: Kobata T.; Ohno K.

Evaluation of MR imaging in hepatoma necrosis caused by percutaneous microwave coagulation therapy
pp. 98-98(1)
Authors: Isobe T.; Tsukada K.; Higashi K.; Nomura T.; Nakao H.; Saso H.; Takahashi T.; Akita S.; Hoshino M.; Takeuchi T.

The ability to detect and diagnose small HCC with MRI fatsat imaging
pp. 98-98(1)
Authors: Kousima O.; Ebara M.; Sanada M.; Akimoto M.; Okabe S.; Fukuda H.; Yosikawa M.; Sugiura N.; Ohto M.

Qualitative assessment of small hepatocellular carcinoma (HCC) by magnetic resonance imaging
pp. 98-98(1)
Authors: Kitamoto M.; Nakanishi T.; Nakashio R.; Kira S.; Tuji K.; Kajiyama G.; Ono T.; Azuma K.; Itoh K.

New diagnostic approach to metastatic liver cancer--angio-helical CT and CT-fluoloscopic marking--
pp. 99-99(1)
Authors: Sugioka A.; Komori Y.; Sugenoya H.; Hasumi A.; Katada K.; Takeshita G.; Tomita K.; Katoh R.

The relationship between distribution of antineoplastic agents injected via the hepatic artery using infusion chamber and postoperative complications
pp. 99-99(1)
Authors: Nishino M.; Hayashi J.; Kakegawa T.; Yamashita Y.

Clinical significance of three-dimensional display of CT, MR and SPECT images by computer graphics in liver diseases
pp. 99-99(1)
Authors: Kashiwagi T.; Nagasawa M.; Toyama T.; Tanaka Y.; Ozaki S.; Ito A.; Naito M.; Ishibashi K.; Azuma M.; Kimm T.; Nakamura H.

Three dimensional image analysis for the support of liver surgery
pp. 99-99(1)
Authors: Maki A.; Takabayashi A.

Renal hemodynamics in cirrhosis evaluated by velocity wave form analysis using duplex doppler ultrasonography
pp. 100-100(1)
Authors: Koda M.; Ikawa S.; Okada K.; Kawasaki H.

Loss of phasic oscillations in doppler waveform of hepatic veins in patients with viral cirrhosis
pp. 100-100(1)
Authors: Kawanaka H.; Hashizume M.; Ohta M.; Kishihara F.; Higashi H.; Tomikawa M.; Sugimachi K.

Spatiotemporal measurement of free radical elimination in the abdomen using an in vivo electron spin resonance imaging system
pp. 100-100(1)
Authors: Togashi H.; Shinzawa H.; Huang Y.; Ohno S.; Sato Y.; Koseki T.; Suzuki K.; Yoshii E.; Matsuhashi T.; Aoyama I.; Kuboki M.; Ishibashi M.; Wakabayashi H.; Takahashi T.; Ogata T.

Quantitative evaluation of hepatic reserve with ^99mTc-DTPA-galactosyl-human serum albumin
pp. 100-100(1)
Authors: Koreeda C.; Ha-kawa S.K.; Sato M.; Tateiwa J.; Mizuno T.; Inoue K.; Tanaka Y.

Prognosis of primary biliary cirrhosis decided from scintigraphy Tc-99m-labelled GSA.
pp. 101-101(1)
Authors: Ogami M.; Shiomi S.; Masaki K.; Jomura H.; Ueda T.; Ikeoka N.; Sakaguchi H.; Takeda T.; Nishiguchi S.; Nakajima S.; Seki S.; Kuroki T.; Kobayashi K.; Ochi H.

Physiological hepatic imaging by positron emission tomography (PET)
pp. 101-101(1)
Authors: Taniguchi H.; Koyama H.; Masuyama M.; Mugitani T.; Koishi Y.; Tanaka H.; Hoshima M.; Miyata K.; Takahashi T.

Estimation of the reticuloendothelial function of the liver and spleen by positron emission computed tomography (PET)
pp. 101-101(1)
Authors: Okada S.; Kuniyasu Y.; Higashi S.; Ohto M.

Clinical significance of the hyperintense basal ganglia on T1-weighted image in patients with chronic liver diseases -- possibility in the early diagnosis of the latent hepatic encephalopathy --
pp. 101-101(1)
Authors: Kuwahara N.; Tanabe M.; Fujiwara A.; Hosaki Y.; Minato T.; Sasaki H.

Evaluation of the hepatic functional reserve and regeneration after hepatectomy by technetium 99m galactosyl human serum albumin dynamic SPECT
pp. 102-102(1)
Authors: Tani T.; Takamura H.; Yamamoto S.; Muraoka K.; Inoue T.; Hashimoto T.; Shimizu K.; Yagi M.; Miyazaki I.; Syuke N.; Hisada K.

Efficasy of 24 week interferon treatment in patients with chronic hepatitis B
pp. 102-102(1)
Authors: Naito M.; Nagasawa M.; Toyama T.; Tanaka Y.; Ito A.; Ozaki S.; Ishibashi K.; Azuma M.; Kashiwagi T.

Results of long term treatment of IFN in chronic active hepatitis B.
pp. 102-102(1)
Authors: Maehara T.; Shimoda K.; Nakajima H.; Nishiyama Y.; Sainokami S.; Hino K.

Evaluation of long term (24 weeks) interferon therapy for type B chronic hepatitis
pp. 102-102(1)
Authors: Karino Y.; Toyota J.; Aso K.; Sato T.; Higashino K.; Furukawa T.; Fujinaga A.; Suga T.; Nagasaka A.; Hige S.; Murashima Y.; Matsushima T.

Twenty-four week administration of IFN-alfa for chronic hepatitis B.
pp. 103-103(1)
Authors: Kanai K.; Matsumoto M.; Kako M.; Aikawa T.; Kawasaki T.; Hino K.; Iwabuchi S.; Tsubouchi H.; Takehira Y.

Clinical evaluation of long-term intermittent administration of interferon-alfa in patients with HBe antigen-positive or negative chronic hepatitis B.
pp. 103-103(1)
Authors: Hakozaki Y.; Kondou T.

Hepatitis B virus variants and response to interferon
pp. 103-103(1)
Authors: Aikawa T.; Kanai K.; Kako M.; Kawasaki T.; Hino K.; Iwabuchi S.; Tsubouchi H.; Takehira Y.

Interferon treatment of chronic hepatitis B and the mutation of pre-core region of hepatitis B virus
pp. 103-103(1)
Authors: Hige S.; Sasaki Y.; Nagasaka A.; Matsushima T.; Asaka M.; Karino Y.; Toyota J.

Effect of -interferon 2b on selected chronic active hepatitis B patients with abruptly elevated aminotrasferases levels
pp. 104-104(1)
Author: Heon J.L.

Interferon therapy in chronic viral B hepatitis in Bangladesh: a preliminary report
pp. 104-104(1)
Authors: M. K.; Ahmad N.; Rahman S.; Zaki K.M.J.; Matin M.A.

High incidence of hepatitis B, C virus and HIV infections among intravenous drug abusers in Guangxi Province, Southern China.
pp. 104-104(1)
Authors: XM. G.; SS. W.; RR. W.; K. C.; Y. W.; HD. P.; GY. H.; Ohno T.; Ohba K.; Orito E.; Suzuki K.; Mizokami M.

Interferon therapy for type-C chronic hepatitis
pp. 104-104(1)
Authors: Arase Y.; Chayama K.; Tsubota A.; Koida I.; Ikeda K.; Saito S.; Matsumoto T.; Murashima N.; Kobayashi M.; Suzuki Y.; Kobayashi M.; Kumada H.

Prediction of HCV-RNA titer change after interferon therapy by PCR-SSCP analysis of 5'-noncoding region
pp. 105-105(1)
Authors: Ishiyama N.; Katayama K.; Kurihara C.; Okamura H.; Yokokawa J.; Nakajima H.; Takahashi S.; Saito S.; Fukushi S.; Hoshino F.B.; Andoh T.; Oya A.

The relationship between the effect of IFN therapy and the change of hepatitis C virus NS5B
pp. 105-105(1)
Authors: Horiike N.; Michitaka K.; Masumoto T.; Itoh Y.; Ohkubo K.; Kurose K.; Iuchi H.; Akbar S.; Onji M.

Amino acid substitutions in NS5A region of HCV-1B are related to its sensitivity to interferon.
pp. 105-105(1)
Authors: Sakuma I.; Enomoto N.; Murakami T.; Asahina Y.; Yamamoto C.; Kurosaki M.; Izumi N.; Marumo F.; Sato C.

Serum HCV-RNA level and the mutation in the interferon sensitivity determining region of chronic hepatitis C patients with genotype 1B infection
pp. 105-105(1)
Authors: Murakami T.; Enomoto N.; Sakuma I.; Izumi N.; Marumo F.; Sato C.

Factors predictive of response to interferon therapy in patients with hepatitis C virus infection and analyses of nucleotide and amino acid sequences obtained from treated patients
pp. 106-106(1)
Authors: Chayama K.; Kobayashi M.; Tsubota A.; Suzuki Y.; Arase Y.; Koida I.; Saitoh S.; Murashima N.; Ikeda K.; Kumada H.; Kobayashi M.; Koike H.; Hashimoto M.

The branched DNA (bDNA) amplification assay as a predictor of response to IFN therapy in children with chronic hepatitis C
pp. 106-106(1)
Authors: Fujisawa T.; Inui A.; Komatsu H.; Miyagawa H.; Ohkawa T.; Ishikawa M.; Kuroki Y.; Onoue M.

Changes of hepatitis C virus (HCV) RNA titers and HCV quasispecies population in the early phase of interferon therapy for chronic hepatitis C
pp. 106-106(1)
Authors: Matsumoto H.; Yamaguchi T.; Chuganji Y.; Momoi M.

Correlation between HCV quasispecies population and the effect of interferon therapy in patients with chronic hepatitis C
pp. 106-106(1)
Authors: Tomida T.; Nakano S.; Takeda I.; Kumada T.; Osada T.; Kiriyama S.; Takahashi M.; Shimada S.; Samori T.; Numaguchi Y.; Toyoda H.

A prediction of efficacy of IFN therapy by disappearance of HCV RNA two weeks after the start of therapy
pp. 107-107(1)
Authors: Tanaka M.; Fujiyama S.; Chikazawa H.; Tomita K.

Improvement of hepatitis C viremia by interferon therapy evaluated by homogenous quantitative assay
pp. 107-107(1)
Authors: Komeda T.; Fukuda Y.; Matsuoka Y.; Kita R.; Sando T.; Furukawa M.; Saitoh J.; Ishiguro T.; Nakao K.

Clinical application of a fluorescence enzyme immunoassay for HCV core protein
pp. 107-107(1)
Authors: Tanaka E.; Matsumoto A.; Kobayashi M.; Kiyosawa K.; Ohta Y.; Hasegawa A.; Kashiwakuma T.; Kohara M.

Usefulness of PAIgG and serous markers of liver fibrosis in determining the effectiveness of interferon therapy for patients with chronic hepatitis C
pp. 107-107(1)
Authors: Iwata N.; Ueda A.; Nakamura Y.; Seto Y.; Kakishita E.

Clinical significance of platelet associated immunoglobulin G in interferon therapy for chronic hepatitis C
pp. 108-108(1)
Authors: Hashimoto Y.; Otsuka T.; Nakajima H.; Katagai K.; Kaneko E.; Takehara K.; Yamada T.; Arai T.; Takagi H.; Takezawa J.; Nagamine T.; Yamada S.; Mori M.

Comparison of bile acid metabolism between responders and nonresponders to IFN in patients with chronic hepatitis C.
pp. 108-108(1)
Authors: Tanaka H.; Murawaki Y.; Yamada S.; Suou T.; Kawasaki H.

The possible role of zinc and metallothionein on the therapeutic effect of INF- to hepatitis C patients.
pp. 108-108(1)
Authors: Nagamine T.; Simoda T.; Kaneko M.; Sekiguti T.; Takehara K.; Yamada T.; Abe T.; Takagi H.; Mori M.; Suzuki K.

Determination and evaluation of serum titers of Human Hepatocyte Grwth factor in Chronic hepatitis C.
pp. 108-108(1)
Authors: Koreeda H.; Yamagami H.; Okubo H.; Aoki H.; Shimizu H.; Moriyama M.; Saitoh H.; Komine F.; Suzuki K.; Tanaka N.; Okubo H.; Ishizuka H.; Arakawa Y.

Effects of interferon- on serum human hepatocyte growth factor levels in patients with chronic hepatitis C
pp. 109-109(1)
Authors: Tsushima H.; Kawata S.; Tamura S.; Ito N.; Shirai Y.; Kiso S.; Oshikawa O.; Matsuzawa Y.

Serum hepatitis C virus(HCV) RNA levels and efficacy of interferon(IFN) therapy for chronic hepatitis C in habitual drinkers.
pp. 109-109(1)
Authors: Ohnishi K.; Matsuo S.; Marutani K.; Itabashi M.; Ohyama N.; Suzuki K.; Ito S.; Fujiwara K.

A new attempt to predict efficacy of interferon (IFN) therapy by use of a scoring system for background factors of patients in whom IFN was ineffective against type C chronic hepatitis
pp. 109-109(1)
Author: Shingami T.

Histological predictors of response to interferon treatment on chronic hepatitis C
pp. 109-109(1)
Authors: Matsunaga T.; Wakahama O.; Nishikawa S.; Higuchi A.; Koike F.; Fukasawa Y.; Hamada Y.

Prediction of response to interferon (IFN) by serum markers of liver fibrosis in chronic hepatitis C.
pp. 110-110(1)
Authors: Nishimori H.; Higuchi K.; Miyabayashi C.; Watanabe A.

Investigation of interferon receptor transcripts in the liver and PBMC as a predicte of interferon response in chronic hepatitis C.
pp. 110-110(1)
Authors: Fukuda R.; Ishimura N.; Nguyen T.; Watanabe M.; Fukumoto S.

Expression of TGF-1 in liver tissues and its prognostic value of IFN treatment in patients with chronic hepatitis C
pp. 110-110(1)
Authors: Shimomura S.; Ueki N.; Ohkawa T.; Asano Y.; Enomoto K.; Kudo K.; Iijima H.; Yamaguchi K.; Matsuda Y.; Yamamoto T.; Amuro Y.; Hada T.; Higashino K.

Prediction of interferon responsiveness in patients with chronic hepatitis C by serum hyaluronate and ICAM-1 levels
pp. 110-110(1)
Authors: Matsunaga T.; Kojima J.; Inoue A.

Study of the cerebral blood flow by ¹²³I-IMP spect during interferon therapy for chronic hepatitis C patients
pp. 111-111(1)
Authors: Sasaki M.; Sata M.; Suzuki H.; Murashima S.; Miyajima I.; Uchimura Y.; Akiyoshi F.; Fukuizumi K.; Ide T.; Yamakawa Y.; Noguchi S.; Tanikawa K.; Ishibashi M.; Uchimura M.; Nakamura J.

Effect of interferon therapy on bone mineral density in chronic hepatitis C patients
pp. 111-111(1)
Authors: Shimotani M.; Yasumura S.; Murata H.; Sato T.; Ishigami T.; Miyamoto T.; Kanda T.; Simizu Y.

Influence on glucose tolerance for interferon therapy in patients with chronic hepatitis C
pp. 111-111(1)
Authors: Kaneko K.; Iijima T.; Nambu M.

Association of platelet GMP140 and thrombocytopenia by interferon therapy in patients with chronic hepatitis C
pp. 111-111(1)
Authors: Takahashi A.; Yamauchi M.; Mizuhara Y.; Shimada S.; Nishikawa F.; Maezawa Y.; Toda G.

Changes in serum lipids in patients with chronic hepatitis C during interferon beta therapy.
pp. 112-112(1)
Authors: Kioka K.; So K.; Moriyoshi Y.; Oka H.; Kuroki T.; Harihara S.; Monna T.; Kobayashi K.

Effects of interferon on cultured human endothelial cells
pp. 112-112(1)
Authors: Ro S.; Hayashi T.; Kamogawa A.; Takatori M.; Mutoh T.; Iiyama K.; Iwabuchi S.; Murayama M.

Mechanism of the changes of platelet counts during interferon therapy in HCV-positive chronic liver disease (CLD)
pp. 112-112(1)
Authors: Azuma K.; Kajiwara E.; Onoyama K.; Akagi K.; Fujishima M.

Clinical findings of blood and progress of ophthalmic lesions during interferon therapy for chronic hepatitis C
pp. 112-112(1)
Authors: Iida T.; Kawatoko T.; Mikasa A.; Okada T.

Autoantibody and target antigen for ana before and after interferon therapy for chronic hepatitis C
pp. 113-113(1)
Authors: Ishiguro N.; Hashimoto E.; Aoka K.; Taniai M.; Katoh J.; Haruta I.; Kamogawa Y.; Katoh T.; Hasegawa K.; Okuda H.; Yamauchi K.; Miyachi K.; Hisamitsu T.; Hayashi N.

Can interferon prevent hepatocarcinogenesis in type C hepatitis?
pp. 113-113(1)
Authors: Takagi H.; Kojima A.; Yamada T.; Kakizaki S.; Abe T.; Shimoda R.; Saitoh S.; Hashimoto Y.; Takehara K.; Nagamine T.; Mori M.; Makita F.; Ohwada S.

Follow-up of patients with chronic hepatitis C treated with interferon: an analysis of long-term responders with positive HCV
pp. 113-113(1)
Authors: Takahashi M.; Yamada G.; Tsugeno H.; Endo H.; Kishi F.; Takatani M.; Takaguchi K.; Manabe K.; Mizuno M.; Tsuji T.

Long-term (5 years in average) follow-up of chronic hepatitis C patients after treatment with interferon
pp. 113-113(1)
Authors: Matsushita M.; Shimazaki T.; Nishikawa J.; Nakao K.; Matsumoto M.; Matsumoto H.; Iwata K.; Kanai K.

Long-term prognosis of chronic liver desease type C after interferon therapy
pp. 114-114(1)
Authors: Chikazawa H.; Fujiyama S.; Sugi K.; Shibata J.; Tomita K.

Long term therapeutic effects of interferon (IFN) on viral hepatitis type C.
pp. 114-114(1)
Authors: Ono T.; Komatsu M.; Kato J.; Ishii T.; Kuramitsu T.; Funaoka M.; Hoshino T.; Masamune O.

The pathological findings on interferon therapy for the patients of chronic hepatitis C
pp. 114-114(1)
Authors: Sugiyama T.; Shimizu M.; Sugiura J.; Yamauchi O.; Yamada M.; Kobayashi S.; Takai T.

Histological response of interferon therapy in chronic hepatitis C
pp. 114-114(1)
Authors: Shimizu T.; Moriyama M.; Suzuki K.; Tanaka N.; Okubo H.; Ishizuka H.; Sugitani M.; Suzuki K.; Uchida T.; Arakawa Y.; Shikata T.

Interferon and combination therapy for chronic hepatitis C
pp. 115-115(1)
Authors: Yatsuhashi H.; Yamasaki M.; Toshihiro T.; Inoue O.; Koga M.; Yano M.

Efficacy of long term interferon- administration for chronichepatitis C
pp. 115-115(1)
Authors: Tanaka N.; Moriyama M.; Suzuki K.; Ohkubo H.; Hideo H.; Arakawa Y.

Combination therapy with beta and alfa-2a interferon (IF) to chronic hepatitis C(CH-C)
pp. 115-115(1)
Authors: Gibo Y.; Nakagawa M.; Furihata Y.; Owa O.; Shimodaira K.; Oguchi S.; Mizokami M.

Interferon-2A therapy for chronic hepatitis C.---effect of its initial daily administration of longer duration according to HCV RNA level and genotypes
pp. 115-115(1)
Authors: Inagaki Y.; Tsukada N.; Yonei Y.; Miyamoto K.; Suzuki O.; Saito H.; Kiryu Y.; Ishii H.; Morizane T.

The method of administration of IFN for chronic hepatitis C.
pp. 116-116(1)
Authors: Ishii T.; Komatsu M.; Ono T.; Funaoka M.; Hoshino T.; Kato J.; Kuramitsu T.; Masmune O.

Recombinant -interferon treatement of chronic hepatitis C -- - a comparison of four protocols according to HCV genotypes and serum HCV-RNA levels
pp. 116-116(1)
Authors: Takahashi M.; Nakano S.; Kumada T.

Long-term follow-up of HCV-infected cirrhotic patients treated with beta-interferon
pp. 116-116(1)
Authors: Imazeki F.; Yokosuka O.; Ohto M.; Omata M.

Antiviral effect of interferon (IFN) in combination with liver extract preparation
pp. 116-116(1)
Authors: Ishiwata Y.; Yokochi S.; Saito H.; Jomori T.; Ebinuma H.; Mitani T.; Tsuchiya M.; Ishii H.

Enhancing effect of the mixture of liver extract and flavin adenin dinucleotide on interferon efficacy in patients with chronic hepatitis
pp. 117-117(1)
Authors: Masuda C.T.; Saito H.; Ebinuma H.; Atsukawa K.; Tada S.; Tsunematsu S.; Tsuchiya M.; Ishii H.

Treatment of chronic hepatitis C with interferon beta.
pp. 117-117(1)
Authors: Jimenez M.; Pallares H.; Gonzalez J.; Lopez F.; Pinar A.; Rebollo J.; Herrerias J.

Twelve months treatment compared to 6 months treatment with - interferon (IFN--2) in chronic hepatitis C (CHC). A multicenter randomised trial.
pp. 117-117(1)
Authors: Manolakopoulos S.; Christias E.; Poulianos G.; Tzathas C.; Pournaras S.; Adamopoulos A.; Spiliadi C.; Tiniakos G.; Perperas A.; Kanaghinis T.; Avgerinos A.

Role of nitric oxide in hepatic microcirculatory dysfunction during endotoxemia
pp. 117-117(1)
Authors: Nishida J.; McCuskey R.S.; Funatsu K.; Takagi T.; Mizuno Y.; Oda M.; Ishii H.

Study on relation between oxygen tension in liver tissue and that in portal vein after ischemia/reperfusion
pp. 118-118(1)
Authors: Urakami A.; Ota T.; Hirai R.; Tsukazaki T.; Matsumoto H.; Soga H.; Nawa S.; Shimizu N.

Effect of central thyrotropin-releasing hormone (TRH) on the hepatic microcirculation
pp. 118-118(1)
Authors: Tamori K.; Yoneda M.; Yokohama S.; Sato Y.; Nakamura K.; Fujita M.; Kimura A.; Baba K.; Saito H.; Akiyama K.; Makino I.

Role of nitric oxide on hepatic arterial blood flow in rats with CCL₄-induced liver injury
pp. 118-118(1)
Authors: Tanaka N.; Tanaka K.; Kondo M.; Sakaguchi T.; Morimoto M.; Numata K.; Okazaki H.; Hoshino M.; Sekihara H.

Relationship between hepatic oxygen metabolism and hepatic venous hemoglobin oxygen saturation after hepatectomy in rats
pp. 118-118(1)
Authors: Yoshioka S.; Miyazaki M.; Itoh H.; Kaiho T.; Ambiru S.; Togawa A.; Ohtsuka M.; Sasada K.; Shimizu M.; Yoshidome H.; Omoto H.; Katoh A.; Nakamura S.; Okuno A.; Nukui Y.; Nozawa S.; Yoshitomi H.; Nakajima N.; Fukuda Y.

Change in plasma concentration of binding free catecholamines in the portal circulation following the portal ligation in rat
pp. 119-119(1)
Authors: Kawai B.; Ohnishi A.; Ohno T.; Matsuo A.; Inoue T.; Tanaka T.

Natriuresis and systemic hemodynamic effects of brain natriuretic reptide(BNP) in rats with cirrhosis
pp. 119-119(1)
Authors: Komeichi H.; Oosuga M.; Terada H.; Satomura K.; Katsuta Y.; Aramaki T.; Moreau R.; Lebrec D.

Increased production of nitric oxide and its role in the portal circulation in cirrhotic rats
pp. 119-119(1)
Authors: Mizumato M.; Arii S.; Furutani M.; Nakamura T.; Monden K.; Ishiguro S.; Fujita S.; Imamura M.

Role of the spleen in the remnant liver dysfunction after extensive hepatectomy: with special reference to expression of adhesion molecules and changes in nitric oxide levels in liver tissue
pp. 119-119(1)
Authors: Kitagawa M.; Sakurai H.; Noguchi T.; Kawarada Y.

Portal hemodynamic changes in patients with normal and injured liver before and after hepatectomy
pp. 120-120(1)
Authors: Takaya Y.; Okamoto E.; Yamanaka N.; Tanaka T.; Oriyama T.; Fujimoto J.; Furukawa K.; Kawamura E.; Ichikawa N.; Tanaka W.; Yasui C.; Ando T.; Kuroda N.; Kitayama Y.; Imakita M.; Okada T.

Hemodynamic change on the spleen under chronic hepatic disorder using positron emission tomography (PET)
pp. 120-120(1)
Authors: Koyama H.; Taniguchi H.; Masuyama M.; Mugitani T.; Koishi Y.; Tanaka H.; Hoshima M.; Miyata K.; Takahashi T.

Clinical characteristics of portal hypertension less than 20 cmH₂O in cirrhosis
pp. 120-120(1)
Authors: Suzuki T.; Sezai S.; Sakurabayashi S.; Yamamoto Y.; Yoshino K.; Hirano M.; Oka H.

Hemodynamics of IV contrast medium in the liver on dynamic CT scan
pp. 120-120(1)
Authors: Ibukuro K.; Tsukiyama T.; Mori K.; Inoue Y.; Fujino H.; Tagawa K.; Unuma T.

Evaluation of portal blood flow in patients with chronic liver diseases using ultrasonic doppler methods
pp. 121-121(1)
Authors: Hatono N.; Sakaguchi S.; Tohara K.; Ueki T.; Ohara J.; Tanaka M.; Miyajima Y.; Nakabayashi S.; Yao T.

The effects of endoscopic variceal sclerotherapy on systemic and splanchnic hemodynamics: correlation with azygos vein blood flow
pp. 121-121(1)
Authors: Shijo H.; Yokoyama M.; Ota K.; Kubara K.; Kokawa H.; Kim T.; Tokumitsu H.; Akiyoshi N.; Nagano Y.; Okumura M.

Effects of misoprostol in patients with liver cirrhosis
pp. 121-121(1)
Authors: Jung M.C.; Kyung S.O.; Sang Y.S.; Sang H.L.; Ha J.C.

Portal flow hemodynamics in non-cirrhotic portal fibrosis by doppler sonography
pp. 121-121(1)
Authors: Chawla Y.; Dhiman R.K.; Saigal S.; Dilawari J.B.

Hemodynamics of blood drainage route (BDR) and therapy for solitary gastric varices
pp. 122-122(1)
Authors: Kokubu S.; Murakami M.; Matsuda M.; Tutihashi K.; Takada M.; Matsumoto E.; Satoh M.; Shibuya A.; Shibata H.; Saigenji K.

The changes of gastric wall blood flows after portal pressure depression in portal hypertension due to liver cirrhosis - comparison of portal pressure and endoscopic and color doppler-endoscopic ultrasonic findings between before and after tipss -
pp. 122-122(1)
Authors: Nishida H.; Nakamata S.; Senjyu S.; Mitamura K.; Ishii M.; Honda M.

A role of portal hemodynanic state in development of portal hypertensive gastro-(colo-)pathy
pp. 122-122(1)
Authors: Mine S.; Yamada S.; Harada Y.; Momosaka Y.; Yoshimi K.; Morimoto I.; Eto S.

The evaluation of the induction of inducible nitric oxide synthase in gastric mucosa and gastric mucosal blood flow in portal hypertensive gastropathy
pp. 122-122(1)
Authors: Irisawa A.; Obara K.; Tojo J.; Ochiai H.; Takiguchi F.; Ohira H.; Nishimaki T.; Kasukawa R.

Long-Term Prognosis of Idiopathic Portal Hypertension(IPH): Comparison with Liver Cirrhosis(LC) and Extrahepatic Portal Obstruction(EHO)
pp. 123-123(1)
Authors: Ohashi K.; Watanabe S.; Orihata G.; Ohura S.; Kojima K.; Fukazawa M.; Beppu T.o.; Futagawa S.

Reciprocal blood flow compensation of portal vein obstruction - angiographi c features
pp. 123-123(1)
Authors: Jae-chun C.; Mi-soo H.

Effects of 9-CIS retinoic acid and synthetic retinoids on the production of TNF- and NO by rat Kupffer cells
pp. 123-123(1)
Authors: Motomura K.; Isobe H.; Sakai H.; Nawata H.

Light and electron microscopic studies on the NOS-positive cells in the human peripheral blood and liver using NADPH-diaphorase histochemistry
pp. 123-123(1)
Authors: Moriyasu H.; Ueda T.; Tomioka H.; Abe Y.; Itoh S.; Katoh T.; Kohri Y.; Kuriyama M.

Functional differences in hepatic macrophages after activation may depend on their expression of CD-14 molecule
pp. 124-124(1)
Authors: Mochida S.; Arai M.; Ohno A.; Suzuki K.; Suzuki H.; Ogata I.; Fujiwara K.

The cross talk between hepatic macrophages and sinusoidal endotherial cells and the microcirculatory disturbances as the mechanism of development of endotoxin induced liver injury.
pp. 124-124(1)
Authors: Fujita S.; Arii S.; Monden K.; Sasaoki T.; Ishiguro S.; Imamura M.

Motogenic action of hepatocyte growth factor for primary cultured hepatocytes and Kupffer cells - - Observation of changes of cell-substractum adhesions, especially, focal contact using confocal laser microscope -
pp. 124-124(1)
Authors: Mizuno K.; Yoneyama K.; Utahasi K.; Mukai T.; Umeda T.; Ishii M.; Mitamura K.

Migration and tube-formation of cultured rat sinusoidal endothelial cells
pp. 124-124(1)
Authors: Shakado S.; Sakisaka S.; Noguchi K.; Ohishi M.; Sasatomi K.; Koga H.; Harada M.; Mimura Y.; Sata M.; Tanikawa K.

Ischemic injury of hepatic sinusoidal endothelial cell in obstructive jaundice
pp. 125-125(1)
Authors: Yoshidome H.; Miyazaki M.; Itoh H.; Kaiho T.; Ambiru S.; Shimizu H.; Nakajima N.

Immunohistochemical study of the liver tissue surrounding metastatic liver cancers
pp. 125-125(1)
Authors: Terayama N.; Terada T.; Nakanuma Y.

Effects of TGF- ₁ and vitamin A on the migration, proliferation and cell death of cultured ito cells.
pp. 125-125(1)
Authors: Wang X.; Watanabe S.; Oide H.; Hirose M.; Suzuki S.; Shimizu H.; Kitamura T.; Miyazaki A.; Komada T.; Kitami N.; Sato N.

Distribution of B7-positive cells in liver tissues of various liver diseases
pp. 125-125(1)
Authors: Shimizu Y.; Nishimori H.; Kashii Y.; Tsukishiro T.; Minemura M.; Miyamoto M.; Higuchi K.; Watanabe A.

Analysis of B-cell clonality in liver-infiltrating lymphocytes in chronic hepatitis
pp. 126-126(1)
Authors: Kashii Y.; Shimizu Y.; Nambu S.; Minemura M.; Higuchi K.; Watanabe A.

Expression of CD80 (B7/BB-1) in liver tissues of patients with chronic hepatitis C
pp. 126-126(1)
Authors: Mochizuki K.; Hayashi N.; Katayama K.; Hiramatsu N.; Kawanishi Y.; Kasahara A.; Fusamoto H.; Yokochi T.; Kamada T.

Distribution of dendritic cells in portal lymphoid aggregates in the tissue with chronic hepatitis C using serial sections
pp. 126-126(1)
Authors: Marui A.; Fukuda Y.; Koyama Y.; Nakano I.; Urano F.; Yamada M.; Katano Y.; Imada K.; Toyoda H.; Ebata M.; Kato O.; Hayakawa T.

Immunohistochemical study of CD45RO-positive memory T cells in chronic hepatitis C; effect of interferon therapy
pp. 126-126(1)
Authors: Yamada M.; Fukuda Y.; Koyama Y.; Nakano I.; Urano F.; Marui A.; Katano Y.; Imada K.; Kato O.; Ebata M.; Toyoda H.; Kumada T.; Hayakawa T.; Nakano S.

Significance of the CD5 positive B cells in chronic hepatitis C
pp. 127-127(1)
Authors: Tsuno S.; Zeniya M.; Ishikawa T.; Hokari A.; Ookawa Y.; Okuaki Y.; Hara M.; Sakaguchi M.; Aizawa Y.; Itsubo M.; Hano H.; Toda G.

Effects of Sho-saiko-to for in vitro cytokine production on peripheral blood mononuclear cells from patients with chronic viral liver diseases.
pp. 127-127(1)
Authors: Yamashiki M.; Nishimura A.; Kosaka Y.

Increment of T cells expressing CD3^LOW, LFA-1^HIGH in inflammatory liver induced by propionibacterium acnes and lipopolysaccharide in neonatally thymectomized A/J mice.
pp. 127-127(1)
Authors: Sanada E.; Watanabe Y.; Kamiyasu M.; Masanaga T.; Naiki M.; Myozaki M.; Kitamoto M.; Nakanishi T.; Kajiyama G.

Clinicopathological and immunogenetical study of Tiopronin induced hepatic injury
pp. 127-127(1)
Authors: Moriguchi M.; Takagi H.; Yamada S.; Sakurai S.; Takezawa J.; Yamada T.; Yuasa K.; Kabeya T.; Kaneko M.; Sugimoto H.; Saitoh S.; Matsumoto T.; Kakizaki A.; Abe T.; Shimoda R.; Takehara K.; Nagamine T.; Mori M.

Alteration in T cell subsets during and after prednisone withdrawal in patients with chronic hepatitis B
pp. 128-128(1)
Authors: Suzuki Y.; Ikeda K.; Saitoh S.; Kobayashi M.; Tsubota A.; Koida I.; Murashima N.; Arase Y.; Chayama K.; Mizoshita K.; Kobayashi M.; Kumada H.

Evidence of apoptosis in peripheral T lymphocytes induced in patients with chronic hepatitis B infection
pp. 128-128(1)
Authors: Nakamura K.; Yuh K.; Shijo H.; Sugyo S.; Iida T.; Kimura A.; Okumura M.

Analysis of T cell receptor usage of T lymphocytes infiltrating in the liver tissue from a patient with chronic type B hepatitis (analysis of CDR3 by inverse polymerase chain reaction)
pp. 128-128(1)
Authors: Maru Y.; Yokosuka O.; Ohto M.; Omata M.

Induction of HLA A2-restricted hepatitis B virus nucleocapsid antigen (HBcAg)-specific cytotoxic T cells (CTL) in patients with chronic hepatitis B
pp. 128-128(1)
Authors: Okumura A.; Iwata K.; Takayanagi M.; Yoshioka K.; Aiyama T.; Kakumu S.

Immune response to viral antigens produced by transgene of full - length HBV in purebred mice
pp. 129-129(1)
Authors: Hasegawa K.; Kato J.; Torii N.; Shizuma T.; Kamogawa Y.; Kato T.; Yamauchi K.; Hayashi N.

Role of vaccination on viral replication in hepatitis B virus transgenic mice
pp. 129-129(1)
Authors: Akbar S.M.F.; Kurose K.; Masumoto T.; Michitaka K.; Horiike N.; Iuchi H.; Ohkubo K.; Itoh Y.; Onji M.

Role of -interferon to overcome immune response defects in hepatitis B virus transgenic mice.
pp. 129-129(1)
Authors: Akbar S.M.F.; Kurose K.; Masumoto T.; Michitaka K.; Horiike N.; Iuchi H.; Ohkubo K.; Itoh Y.; Onji M.

Classification of HBV pre S2 peptide types by using PCR technique and its clinical significance
pp. 129-129(1)
Authors: Nishikawa M.; Yonemitsu H.; Kimura T.; Ryo K.; Sekiya H.; Haruta I.; Kamogawa Y.; Kato T.; Yamauchi K.; Hayashi N.

Chronic active hepatitis B patients of acute exacerbation with or without abrupt onset of severe jaundice
pp. 130-130(1)
Authors: Heon J.L.; Jeong I.S.

T cell response to HBsAg in chronic hepatitis B infection
pp. 130-130(1)
Authors: Ahn S.Y.; Park B.C.

Failure of protection by long persisting human anti-HEV(IgG) against HEV infection in rhesus monkeys.
pp. 130-130(1)
Authors: Chauhan A.; Dilawari J.B.; Saroa S.R.; Masih B.; Mukesh M.

Serum soluble HLA class I and II molecules in liver disease
pp. 130-130(1)
Authors: Terada S.; Morishita T.; Westhoff U.; Ishii H.

Identification of 'native' peptides bound to class I HLA molecules on hepatocyte membrane
pp. 131-131(1)
Authors: Sakuma J.; Yokosuka O.; Imazeki F.; Tagawa M.; Ehata T.; Miyagi M.; Kikuchi M.; Imagawa K.; Takizawa T.; Aihara M.; Tomishige T.; Seike Y.; Shimizu F.; Omata M.

Hepatitis C virus-specific cytotoxic T lymphocyte responses and viral status in chronic hepatitis C virus infection
pp. 131-131(1)
Authors: Hiroishi K.; Kojima M.; Kita H.; Okamoto H.; Moriyama T.; Kaneko T.; Ando K.; Aikawa T.; Ohnishi S.; Tanaka N.; Mitamura K.; Imawari M.

IFN- and - production in patients with chronic hepatitis C.
pp. 131-131(1)
Authors: Uno K.; Kakimi K.; Suginoshita Y.; Moriyasu F.; Kishida T.

Effect of interferon therapy on the response of PBMC from chronic hepatitis C patients against HCV core-derived peptides
pp. 131-131(1)
Authors: Arichi T.; Shirai M.; Manabe T.; Okada H.; Fujii O.; Arima K.; Watanabe S.; Nishioka M.

Analysis of TCR V gene in peripheral T lymphocytes before and after interferon therapy of patients with chronic hepatitis type C
pp. 132-132(1)
Authors: Sugyo S.; Yuh K.; Shijo H.; Nakamura K.; Kimura N.; Okumura M.

Apparent involvement of cellular immunity in the mechanism of hepatic cell damage and dysfunction associated with HCV hepatitis(CH-C) patients.
pp. 132-132(1)
Authors: Shimoide Y.; Oketani M.; Shou Y.; Miyazaki H.; Arima T.; Shingami T.; Obara T.; Hino K.; Okumura K.

Effect of bile acids on major histocompatibility complex (MHC) class I gene expression
pp. 132-132(1)
Authors: Hirano F.; Makino Y.; Okamoto K.; Miura T.; Inaba M.; Tanaka H.; Makino I.

Intrahepatic lymphocytes following 70% partial hepatectomy in the rats: extrathymic T cells in the rats
pp. 132-132(1)
Authors: Sato Y.; Farges O.; Buffello D.; Hatakeyama K.; Bismuth H.

Relationship between Quantitation of Hepatitis C Virus RNA by Competitive PCR, and Its Genotype and Regional Specific Ab Responses
pp. 133-133(1)
Authors: Seung K.Y.; Young M.P.; Kyu S.S.; Boo S.K.

Could hyaluronic acid serve as a marker of warm ischemic injury in the grafted liver?
pp. 133-133(1)
Authors: Kimura J.; Nakajima Y.; Ito K.; Tamura M.; Kamachi H.; Kon H.; Nishibe M.; Uchino J.

The F(ab')2 fragment of an anti-ICAM-1 monoclonal antibody attenuates liver injury after orthotopic liver transplantation
pp. 133-133(1)
Authors: Takei Y.; Nishimura Y.; Kawano S.; Goto M.; Nagano K.; Tsuji S.; Nagai H.; Ohmae A.; Fusamoto H.; Kamada T.

Cold storage-induced alteration of hepatic energy metabolizm in isolated and perfused rat liver: influence of leukocyte accumulation
pp. 133-133(1)
Authors: Higuchi H.; Kurose I.; Miura S.; Kato S.; Ishii H.

Donor des-gamma-carboxy prothrombin level is correlated with early graft function after orthotopic liver transplantation
pp. 134-134(1)
Authors: Suehiro T.; Boros P.; Sheiner P.; Emre S.; Guy S.; Schwartz M.; Miller C.

Blood hyaluronic acid levels for assessment of early graft function in clinical liver transplantation
pp. 134-134(1)
Authors: Suehiro T.; Boros P.; Emre S.; Sheiner P.; Guy S.; Schwartz M.; Miller C.

Clinical evaluation of transplanted liver function by measurement of indocyanine green (ICG) concentration in bile
pp. 134-134(1)
Authors: Mizoe A.; Todo S.; Tsubono T.; Kanematsu T.

Changes of nitric oxide levels and sinusoidal endothelial cell function in the trafted liver after orthotopic liver transplantation in dogs
pp. 134-134(1)
Authors: Noguchi T.; Kitagawa M.; Sakurai H.; Ito F.; Yokoi H.; Kawarada Y.

The protective effects of prostaglandin E1 on energy status and protein synthesis in acute ischemic liver.
pp. 135-135(1)
Authors: Nakagohri T.; Asano T.; Uematsu T.; Hasegawa M.; Maruyama M.; Miyauchi H.; Iwashita T.; Isono K.; Ogawa E.

Relationships between nitroxide radical pharmacokinetics and the changes of pO₂ in a mouse liver using in vivo ESR spectroscopy
pp. 135-135(1)
Authors: Inaba K.; Nakashima T.; Shima T.; Sakamoto Y.; Okanoue T.; Kashima K.

Expressions of cytochrome P450 within intrasplenically transplanted fetal hepatocytes
pp. 135-135(1)
Authors: Kato K.; Kasai S.; Matsuda M.; Onodera K.; Sawa M.; Michio M.; Hodgson W.

The effect of h-HGF for survival and proliferation of intrasplenically transplanted hepatocytes in rat
pp. 135-135(1)
Authors: Nakazawa F.; Kato K.; Kasai S.; Onodera K.; Sawa M.; Kawabata N.; Bojian J.; Mito M.

HSS induced proliferation of intrasplenically transplanted hepatocytes
pp. 136-136(1)
Authors: Sawa M.; Jiang B.; Tomita I.; Kino Y.; Hashimoto M.; Mamiya N.; Nakazawa F.; Kasai S.; Mito M.

Effect of anti-CD4 monoclonal antibody (OX-38) therapy after liver transplantation in rats
pp. 136-136(1)
Authors: Yamaguchi J.; Gu W.; Yamamoto T.; Watanabe Y.; Mizoe A.; Azuma T.; Fujioka H.; Furui J.; Kanematsu T.

Hepatocyte transplantation - Indian experience
pp. 136-136(1)
Authors: Habibulla C.M.; Ayesha Q.; Hasan S.I.; Lahiri S.; Khaleelur-Rehman; Srinivas V.K.; Khan A.A.; Mohsin S.

Preservation and transportation of graft for cadaveric liver transplant in Japan
pp. 136-136(1)
Authors: Hoshima M.; Taniguchi H.; Takahashi T.

Current status of a cadaveric liver transplantation program in Japan
pp. 137-137(1)
Authors: Yanaga K.; Nishizaki T.; Soejima Y.; Yoshizumi T.; Sugimachi K.; Kashiwagi S.

Staging and grading in chronic hepatitis
pp. 137-137(1)
Authors: Inoue O.; Yatsuhashi H.; Yamasaki M.; Koga M.; Yano M.

Evaluation of three-dimensional reconstruction of sinusoids by confocal laser reflection microscopy
pp. 137-137(1)
Authors: Yoneyama K.; Baba T.; Utahashi K.; Mizuno K.; Umeda T.; Mukai T.; Ishii M.; Mitamura K.

Histopathological Assessment of the Liver of Patients with Chronic Hepatitis C Before and After Interferon (IFN) Treatment: HAI score and evaluation of lymphoid follicle, fatty change, and iron deposition
pp. 137-137(1)
Authors: Iiyama K.; Maeyama S.; Takahashi Y.; Kishi M.; Aida Y.; Uchikoshi T.; Yoshida H.; Iwabuchi S.; Murayama M.

Chronological changes of bile ducts and peribiliary vascular plexuses in rats after bile duct ligation
pp. 138-138(1)
Authors: Haratake J.; Nakano S.

Distinction between lymph vessels and portal vein branches in portal tracts using immunohistochemistry for -smooth muscle actin
pp. 138-138(1)
Authors: Oikawa H.; Masuda T.; Sato S.; Satodate R.

Cell proliferation and apoptosis of intrahepatic bile duct of rats during its development and maturation
pp. 138-138(1)
Authors: Sanzen T.; Terada T.; Nakanuma Y.

Immunohistochemical Expression of HLA-DR Antigen in the Portal Area of the Liver in Patients with Biliary Atresia (BA); Comparative study with congenital cystic dilatation of common bile duct (CC).
pp. 138-138(1)
Authors: Koike J.; Maeyama S.; Aida Y.; Takakuwa T.; Uchikoshi T.; Nakada M.; Fujioka T.; Nakada N.

Histometrical study on repeated liver biopsies of chronic hepatitis C
pp. 139-139(1)
Authors: Kage M.; Shimamatsu K.; Kojiro M.; Inoue O.; Yano M.

The characters and the functions of hepatic lymphomyeloid cells
pp. 139-139(1)
Authors: Arai Y.; Kobayashi E.; Nozawa M.; Miyata M.; Yamanaka T.

Direct activation of the chloride channel in guinea-pig hepatocytes by protein kinase C
pp. 139-139(1)
Authors: Koumi S.-i.; Sato R.; Aramaki T.

Effect of catalase and -tocopherol on cultured hepatocytes
pp. 139-139(1)
Authors: Nishikawa M.; Matsushita M.; Takahashi M.; Taguchi K.; Koike M.; Kamachi H.; Kon H.; Uchino J.

A new liver support system composed of functional human liver cells and a radial flow bioreactor for clinical use
pp. 140-140(1)
Authors: Kawada M.; Aizaki H.; Fukaya K.; Niiya M.; Shimiz u K.; Matsuura T.; Sujino H.; Hasumura S.; Nagamori S.

Hepatic disease in 39 autopsied cases of acquired immune deficiency syndrome
pp. 140-140(1)
Authors: Shibayama T.; Hayashi S.; Saeki S.; Tanaka T.; Ootake H.; Tanaka S.; Igari T.; Agisawa A.; Negishi M.; Masuda G.; Koike M.

Investigation of hepatitis virus infection in cases of autopsies
pp. 140-140(1)
Authors: Takamatsu J.; Tokudome S.; Okudaira M.; Toda G.

Abnormal expression of MUC1 mucin core protein and mature MUC1 mucin in biliary epithelial cells in cystic liver disease
pp. 140-140(1)
Authors: Sasaki M.; Nakanuma Y.

Alterations of ornithine decarboxylase gene in human hepatocellular carcinoma
pp. 141-141(1)
Authors: Koh N.; Tamori A.; Nishiguchi S.; Seki M.; Kuroki T.; Kobayashi K.; Kinoshita H.; Otani S.

Androgen supplement for castrated TGF transgenic male mice restored hepatic tumorignesis.
pp. 141-141(1)
Authors: Matsumoto T.; Saitoh S.; Moriguchi M.; Shimoda R.; Takehara K.; Nagamine T.; Mori M.; Takagi H.

Endothelin-1 is an autocrine growth factor for hepatocellular carcinoma.
pp. 141-141(1)
Authors: Ishibashi M.; Takuwa Y.; Furue H.; Miura H.; Onishi M.; Yamaji T.

Farnesy protein transferase inhibitor manumycin inhibits the ras farnesylation and cell growth, but not the nuclear lamin farnesylation in human tumor cells
pp. 141-141(1)
Authors: Nagase T.; Kawata S.; Tamura S.; Matsuda Y.; Inui Y.; Yamasaki E.; Ishiguro H.; Ito T.; Matsuzawa Y.

Involvement of pp60^C-SRC, C- terminal SRC kinase(CSK) and annexin II (AXII) in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma
pp. 142-142(1)
Authors: Masaki T.; Tokuda M.; Okada M.; Watanabe S.; Kouno K.; Arima K.; Shirai M.; Okada H.; Hatase O.; Nishioka M.

Decreased expression and point mutation of CIP1/WAF1 gene in human hepatocellular carcinomas
pp. 142-142(1)
Authors: Furutani M.; Arii S.; Tanaka H.; Higashitsuji H.; Mise M.; Niwano M.; Harada T.; Ishigami S.; Imamura M.; Fujita J.

Repression of glucocorticoid-inducible gene expression by a novel DNA-binding protein in a nuclear extract from the rat hepatoma cell line M1.19
pp. 142-142(1)
Authors: Tanaka H.; Makino Y.; Okamoto K.; Inaba M.; Hirano F.; Makino I.

Expression of thymosin 4 gene during differentiation of HuH-7 cells
pp. 142-142(1)
Authors: Matsunaga T.; Kudo J.; Hayashida K.; Ishibashi H.; Niho Y.

Genetic alteration of P16 (MTS1) and cyclin E in HCC and CCC
pp. 143-143(1)
Authors: Kita R.; Nishida N.; Matsuoka Y.; Komeda T.; Sando T.; Furukawa M.; Fukuda Y.; Nakao K.; Ishizaki K.

Expression of HNF-1/vHNF-1 ratio is strongly linked to histological differentiation of hepatocellular carcinoma and hepatoblastoma
pp. 143-143(1)
Authors: Ninomiya T.; Hayashi Y.; Ohta K.; Saijoh K.; Seo Y.; Sugano M.; Yoon S.; Itoh H.; Kasuga M.

Cyclin a expression in hepatocellular carcinoma and possible mechanism of its overexpression
pp. 143-143(1)
Authors: Masaki N.; Ogata I.; Bandai Y.; Kurokawa K.; Makuuchi M.; Fujiwara K.

Restriction landmark genomescanning analysis of chromosomal DNA in hepatocellular carcinoma
pp. 143-143(1)
Authors: Hanafusa T.; Yumoto Y.; Hada H.; Shinji T.; Morita T.; Shiraha H.; Tamura T.; Iwasaki Y.; Koide N.; Nagai H.; Matsubara K.; Tsuji T.

Reduction of telomeres in chronic liver diseases.
pp. 144-144(1)
Authors: Kitada T.; Seki S.; Sakaguchi H.; Kawakita N.; Ichikawa Y.; Kuroki T.; Kobayashi K.; Monna T.

Evaluation of malignant potential and intratumoral heterogeneity in hepatocellular carcinoma by chromosomal numerical analysis
pp. 144-144(1)
Authors: Kimura H.; Kagawa K.; Deguchi T.; Nakajima T.; Kakusui M.; Ohkawara T.; Katagishi T.; Okanoue T.; Kashima K.

Effect of IL-8 on autocrine growth and production of tumor - associated substances in human liver tumor cell lines
pp. 144-144(1)
Authors: Miyamoto M.; Shimizu Y.; Kashii Y.; Nambu S.; Higuchi K.; Watanabe A.

The role of interferon regulatory factor-1 on hepatoma cell growth.
pp. 144-144(1)
Authors: Tada S.; Saito H.; Tsunematsu S.; Masuda T.; Atsukawa K.; Ebinuma H.; Kumagai N.; Tsuchimoto K.; Morizane T.; Ishii H.

Conversion of sarcomatous cholangiocarcinoma cells to hepatocyte lineage
pp. 145-145(1)
Authors: Enjoji M.; Honda M.; Sakai H.; Nawata H.

HGF and c-met expression in LEC rats in various phases of liver diseases
pp. 145-145(1)
Authors: Nakayama N.; Kashiwazaki H.; Kobayashi N.; Hamada J.; Itakura Y.; Matsumoto K.; Nakamura T.; Koike T.; Takeichi N.

The effect of hepatocyte growth factor on various human hepatocellular carcinoma cell lines in vitro
pp. 145-145(1)
Authors: Iemura A.; Yano H.; Haramaki M.; Momosaki S.; Ogasawara S.; Higaki K.; Kojiro M.

Inhibition of proliferation and development of hepatocellular carcinoma by hepatocyte growth factor in transgenic mice
pp. 145-145(1)
Authors: Shiota G.; Okano J.; Kawasaki H.

Expression of basic fibroblast growth factor and its receptor in human hepatocellular carcinoma cell lines
pp. 146-146(1)
Authors: Ogasawara S.; Yano H.; Iemura A.; Haramaki M.; Momosaki S.; Higaki K.; Kojiro M.

Induction of apoptosis by hepatocyte growth factor (HGF) and interferon (IFN) in HEP G2 cells.
pp. 146-146(1)
Authors: Yanagawa K.; Yamashita T.; Yada K.; Takeuchi K.; Ohira M.; Ishikawa T.; Sowa M.

Enhancement of anti-Fas antigen-mediated apoptosis in human hepatocellular carcinoma cell lines in the presence of the protein synthesis inhibitor cycloheximide
pp. 146-146(1)
Authors: Yano H.; Iemura A.; Fukuda K.; Haramaki M.; Momosaki S.; Ogasawara S.; Higaki K.; Kojiro M.

Induction of apoptosis by deprivation of transforming growth factor-alpha in newly established human hepatocellular carcinoma.
pp. 146-146(1)
Authors: Sakai Y.; Seki S.; Kawakita N.; Kitada T.; Sakaguchi H.; Kuroki T.; Kobayashi K.; Tsutsui H.; Monna T.

Analysis for cell proliferation and morphological change after introduction of p53 gene
pp. 147-147(1)
Authors: Terai S.; Matsuzaki Y.; Kimura T.; Kato A.; Masuhara M.; Yamasaki T.; Kurokawa F.; Yasunaga M.; Okita K.

Delivery of transferrin-DNA conjugate to hepatoma via transferrin receptor
pp. 147-147(1)
Authors: Fujiwara H.; Neda H.; Hirayama M.; Sato Y.; Matsuyama T.; Teramoto J.; Koshita Y.; Watanabe N.; Kohgo Y.; Niitsu Y.

Heparin-binding EGF-like growth factor-psudomonas exotoxin, a new targeted toxin for the therapy of liver cell cancer
pp. 147-147(1)
Authors: Klagsbrun M.; Mesri E.A.; Kreitman R.J.; Pastan I.; Ono M.; Kohgo Y.

Gene therapy for hepatocellular carcinoma by use of a suicide gene: investigation on in vitro and in vivo bystander effect
pp. 147-147(1)
Authors: Kuriyama S.; Masui K.; Nakatani T.; Sakamoto T.; Tominaga K.; Yoshikawa M.; Tsujii T.

Mechanism analysis of acquirement of ganciclovir resistance in viral thymidine kinase gene-transduced hepatoma cells
pp. 148-148(1)
Authors: Sakamoto T.; Kuriyama S.; Masui K.; Tominaga K.; Tsujii T.

A suicide gene therapy of metastasized liver tumors
pp. 148-148(1)
Authors: Matsuyama T.; Koshita Y.; Y. L.; Neda H.; Hirayama M.; Sato Y.; Teramoto J.; Watanabe N.; Niitsu Y.; Wakimoto H.; Hamada H.

Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human -fetoprotein gene promoter
pp. 148-148(1)
Authors: Ido A.; Nakata K.; Kato Y.; Nakao K.; Ishii N.; Nagataki S.

Localization of 92KD gelatinase (MMP9) gene transcripts in human hepatocellular carcinoma.
pp. 148-148(1)
Authors: Ashida K.; Nakatsukasa H.; Higashi T.; Hino N.; Nouso K.; Urabe Y.; Yoshida K.; Kinugasa N.; Uematsu S.; Tsuji T.

Clinicopathological significance of MMP-2,9, and MT-MMP mRNA expressions in hepatocellular carcinoma and the effect of MMP-9 inhibitor
pp. 149-149(1)
Authors: Harada T.; Arii S.; Mise M.; Higashitsuji H.; Furutani M.; Ishigami S.; Niwano M.; Imamura M.; Tamaki K.; Tanzawa K.

Molecular mechanisms of intrahepatic metastasis of hepatocellular carcinoma
pp. 149-149(1)
Authors: Osada T.; Sakamoto M.; Nagashima I.; Muto T.; Hirohashi S.

Effects of angiogenesis inhibitor and anti-cancer drug to suppress hepatic recurrence after partial hepatectomy for liver metastases in rabbits.
pp. 149-149(1)
Authors: Mugitani T.; Taniguchi H.; Koishi Y.; Masuyama M.; Tanaka H.; Koyama H.; Hoshima M.; Miyata K.; Takahashi T.

Messenger RNA expression of vascular endothelial growth factor (VEGF) in human hepatoma-derived cell line
pp. 149-149(1)
Authors: Kawahara H.; Sawada M.; Chen W.B.; Tsuchishima M.; Ito T.; Ueshima Y.; Tsutsumi M.; Matsuda Y.; Takase S.

The accelerating effect of ischemia-reperfusion injury on liver metastasis of rat ascitic hepatoma
pp. 150-150(1)
Authors: Maeda I.; Ku Y.; Shiotani M.; Tominaga M.; Kitagawa T.; Iwasaki T.; Kuroda Y.; Saitoh Y.

Analysis of invasive activity of human hepatic cancer cell lines
pp. 150-150(1)
Authors: Kamiyama T.; Une Y.; Nishibe M.; Shimamura T.; Haneda T.; Nakanishi K.; Uchino J.

Immunohistochemical detection of the receptor for urokinase plasminogen activator in hepatocellular carcinoma
pp. 150-150(1)
Authors: Akahane T.; Ishii M.; Ohtani H.; Toyota T.

Role of serum soluble adhesion molecules in the recurrence and progression of hepatocellular carcinoma after resection
pp. 150-150(1)
Authors: Une Y.; Haneda T.; Kamiyama T.; Shimamura T.; Nishibe M.; Nakanishi K.; Saiki I.; Matsushita M.; Uchino J.

Correlation between tumor growth and angiogenesis in hepatic tumors
pp. 151-151(1)
Authors: Ueda K.; Itou Y.; Murakami M.; Fukoue Y.; Kobayashi A.; Kusano M.

Detection and evaluation of serum and intrahepatic ICAM-1 in hepatocellular carcinoma
pp. 151-151(1)
Authors: Shioda A.; Moriyama M.; Yamagami H.; Saitoh H.; Suzuki K.; Tanaka N.; Okubo H.; Ishizuka H.; Sugitani M.; Suzuki K.; Uchida T.; Arakawa Y.; Shikata

Surface expression of B7 on human liver tumor cells and its modulation by cytokines
pp. 151-151(1)
Authors: Shimizu Y.; Kashii Y.; Tsukishiro T.; Nishimori H.; Minemura M.; Miyamoto M.; Higuchi K.; Watanabe A.

Antitumor activity of human IL2-activated natural killer cells (A-NK) against hepatocellular carcinoma (HCC)
pp. 151-151(1)
Authors: Yasumura S.; Higuchi K.; Atarashi Y.; Watanabe A.; Vujanovic N.; Whiteside T.

Basic studies on GcMAF, a new immunotherapeutic agent, in treatment of liver cancer
pp. 152-152(1)
Authors: Homma S.; Toda G.; Yamamoto N.

Possible involvement of transforming growth factor-1 in the immunosuppression in patients with advanced malignant diseases
pp. 152-152(1)
Authors: Ito N.; Kawata S.; Tamura S.; Kiso S.; Tsushima H.; Oshikawa O.; Matsuzawa Y.

Changes of immunological parameters after hepatectomy for hepatocellular carcinoma and effects of ulinastatin
pp. 152-152(1)
Authors: Takeuchi Y.; Nonami T.; Yoshida N.; Harada A.; Nakao A.; Takagi H.

Affinities of polymers having galactose with hepatocytes and hepatoma cell lines
pp. 152-152(1)
Authors: Yamamoto M.; Ichinose K.; Ishii N.; Goto M.; Akaike T.; Kanematu K.

The secretion of procathepsin B and changes in its sugar moiety in cultured hepatoma cells
pp. 153-153(1)
Authors: Liu L.; Higashi T.; Uematsu S.; Yoshida K.; Kinugasa N.; Urabe Y.; Ashida K.; Hino N.; Nouso K.; Nakatsukasa H.; Tsuji T.

The dynamics of serum AFP, ALF and IAP during experimental hepatocarcinogenesis in rats with 3' -ME-DAB.
pp. 153-153(1)
Authors: Nakayama T.; Aoki H.; Matsuoka S.; Gotoh I.; Taga H.; Ishizuka H.; Arakawa Y.; Hibi N.

Glycosylation patterns of alpha-fetoprotein (AFP) in special reference to disease category.
pp. 153-153(1)
Authors: Aoyagi Y.; Naitoh A.; Yanagi M.; Suda T.; Isokawa O.; Igarashi H.; Suzuki Y.; Asakura H.

Altered glycosylation of serum transferrin as indices of therapeutic effects on hepatocellular carcinoma
pp. 153-153(1)
Authors: Suzuki Y.; Aoyagi Y.; Nitoh A.; Isokawa O.; Igarashi H.; Yanagi M.; Suda T.; Mori S.; Asakura H.

Association between urinary free fucose and serum levels of glycoprotein-bound fucose in patients with chronic liver disease
pp. 154-154(1)
Authors: Nishikawa F.; Yamauchi M.; Takagi M.; Searashi Y.; Sato S.; Maezawa Y.; Inoue T.; Uchida M.; Nakahara M.; Kimura K.; Toda G.; Usui K.; Kato I.

Application of immuno-PCR assay to detect an ultra-low level plasma protein, pivka-II
pp. 154-154(1)
Authors: Tsujii H.; Okamoto Y.; Nakano H.; Watanabe K.; Naraki T.

Serum anti-p53 antibody in patients with hepatocellular carcinoma
pp. 154-154(1)
Authors: Saeki R.; Terasaki S.; Urabe K.; Inagaki Y.; Kaneno S.; Lin Y.; Ohno H.; Unoura M.; Murakami S.; Kobayashi K.

Prospective analysis on the course of patients with hepatocellular carcinoma (HCC) by AFP mRNA in blood
pp. 154-154(1)
Authors: Matsumura M.; Niwa Y.; Tanaka T.; Ogura K.; Imamura M.; Kanai H.; Kato N.; Shiina S.; Yoshida H.; Kawabe T.; Ohta S.; Shiratori Y.; Sezai S.; Hirano S.; Omata M.

Clinical significance of serum AFP -mRNA in the hepatocellular carcinoma (HCC) patient
pp. 155-155(1)
Authors: Kanbara Y.; Maekawa Y.; Nakaya S.; Ishikawa Y.; Toda K.

Appearance of hepatocellular carcinoma cells along with a course of invasive therapy
pp. 155-155(1)
Authors: Komeda T.; Fukuda Y.; Matsuoka Y.; Kita R.; Sando T.; Furukawa M.; Nakao K.

Genetic alterations of Nm23-H1 gene in hepatocellular carcinoma
pp. 155-155(1)
Authors: Fujimoto Y.; Nishimori H.; Kohda H.; Mizuno M.; Kawashima T.; Torimoto Y.; Hasebe C.; Sekiya C.; Kohgo Y.

Detection of Intrahepatic ICAM-1 in Rats with DEN-Induced Cancer
pp. 155-155(1)
Authors: Moriyama M.; Suzuki K.; Okubo H.; Shimizu T.; Matsumura H.; Tanaka N.; Okubo H.; Sugitani M.; Suzuki K.; Uchida T.; Arakawa Y.; Shikata T.

Presence of inducible nitric oxide syntase immunoreactivity in hepatocytes from various liver diseases
pp. 156-156(1)
Authors: Kono T.; Yamamoto Y.; Kamiya M.; Ando N.; Kotani H.; Kino S.; Kakisaka A.; Kasai S.; Mito M.; Iwamoto J.

Expression of the BCR protein as a signal transduction product in Human Hepatocellular Carcinoma
pp. 156-156(1)
Authors: Miyazaki Y.; Ichida T.; Mathuda Y.; Sato T.; Sugitani S.; Yonekura K.; Sugiyama M.; Asakura H.; Ishihara K.

Quantification of -fetoprotein (AFP) and albumin mRNAs in human hepatocellular carcinoma (HCC)
pp. 156-156(1)
Authors: Niwa Y.; Matsumura M.; Okudaira T.; Kato N.; Shiina S.; Kawabe T.; Ota S.; Shiratori Y.; Omata M.

Detection of albumin and AFP mRNA in the circulation: an indicator of hepatic injury in patients with acute viral hepatitis
pp. 156-156(1)
Authors: Sakaguchi T.; Tanaka K.; Arata S.; Kondo M.; Morimoto M.; Saito S.; Tanaka N.; Mitui K.; Okazaki H.; Hoshino M.; Sekihara H.

Correlation of sinusoidal capillarization and arterial blood supply with the stages of hepatocarcinogenesis of rat
pp. 157-157(1)
Authors: Yamamoto T.; Ikebe T.; Kaneda K.; Kinoshita H.; Hirohashi K.; Sakurai M.

Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma.
pp. 157-157(1)
Authors: Kira S.; Tsuji K.; Nakashio R.; Kitamoto M.; Nakanishi T.; Kajiyama G.; Suemori S.

Detection of Intrahepatic Fas Antigen in Hepatocellular Carcinoma.
pp. 157-157(1)
Authors: Moriyama M.; Shimizu T.; Shioda A.; Komine F.; Suzuki K.; Tanaka N.; Okubo H.; Ishizuka H.; Sugitani M.; Suzuki K.; Uchida T.; Arakawa Y.; Shikata T.

Analysis of hyperplastic foci in the liver by flow-cytometric measurement and AgNOR staining
pp. 157-157(1)
Authors: Ikebe T.; Wakasa K.; Haba T.; Yamamoto T.; Shuto T.; Okuda T.; Hirohashi K.; Kinosita H.; Sakurai M.

Overexpression of 27-kDa heat shock proteins in cholangiocarcinoma: A immunohistochemical study
pp. 158-158(1)
Authors: Wakayama T.; Minato H.; Nakanuma Y.

P-glycoprotein expression in hepatocellular carcinoma-from the view of histological differentiation and chemotherapy-
pp. 158-158(1)
Authors: Tada K.; Iwai M.; Ishii Y.; Kitagawa Y.; Kashiwadani M.; Nakashima T.; Okanoue T.; Kashima K.

Expression of MAGE-1 gene in hepatocellular carcinoma
pp. 158-158(1)
Authors: Yamashita N.; Hayashida K.; Ishibashi H.; Niho Y.; Kudo J.; Takenaka K.; Itoh K.

A clinicopathological study on combined hepatocellular and cholangiocarcinoma.
pp. 158-158(1)
Authors: Taguchi J.; Nakashima O.; Okudaira S.; Watanabe J.; Iha H.; Tanaka M.; Takazawa T.; Kojiro M.

Establishment and characterization of sarcomatous cholangiocarcinoma cell line (ETK-1)
pp. 159-159(1)
Authors: Honda M.; Enjoji M.; Sakai H.; Nawata H.

Analysis of HBV-DNA precore mutation in chronic liver disease developed to hepatocellular carcinoma
pp. 159-159(1)
Authors: Yamamoto K.; Kato M.; Kurosawa K.; Ishida H.; Nakamura E.; Shirai Y.; Park N.; Shiomi M.; Michida T.; Kaneko A.; Hayashi N.; Ikeda M.; Masuzawa M.

Polymerase chain reaction analysis of hepatitis B virus DNA sequences in hepatocellular carcinomas from patients negative for hepatitis B surface antigen and positive for anti-HCV antibody
pp. 159-159(1)
Authors: Nambu S.; Aiba N.; Nishimori H.; Kashii Y.; Higuchi K.; Watanabe A.

Selection of HBV PreC/C gene mutants in the tumor tissue of patients positive or negative for HBsAg
pp. 159-159(1)
Authors: Minami M.; Okanoue T.; Kashima K.; Paterlini P.; Brechot C.

Involvement of hepatitis B virus for the development of hepatocellular carcinoma-detection of integrated hepatitis B viral sequences in tumor tissue.
pp. 160-160(1)
Authors: Urashima T.; Saigo K.; Kobayashi S.; Matsubara H.; Koide Y.; Asano T.; Isono K.

Cellular protein(s) related to genomic instability in HBV-induced hepatocarcinogenesis.
pp. 160-160(1)
Authors: Kajino K.; Aoki H.; Hino O.

Molecular biological characteristics of model cells of hepatitis B virus(HBV)-induced direct hepatocarcinogenesis --HBV-DNA integration analysis by fish method--.
pp. 160-160(1)
Authors: Baba M.; Nagai H.; Hasegawa H.; Nakayabu M.; Kumazawa M.; Shima T.

Comparison of core gene sequences of hepatitis C virus (HCV) between Japanese and Chinese patients with hepatocellular carcinoma (HCC)
pp. 160-160(1)
Authors: Horie T.; Horie C.; Shiba M.; Yasuda M.; Nishikado T.; Honda H.; Shimizu I.; Ito S.

Detection of hepatitis B virus genome in hepatocellular carcinoma from both hepatitis B surface antigen- and antibody to hepatitis C virus-negative patients: a study using polymerase chain reaction
pp. 161-161(1)
Authors: Kamito H.; Daikoku M.; Inokuchi K.; Matsumoto T.; Nakao K.; Kato Y.; Nakata K.; Ishii N.; Nagataki S.

Genetic variations of the precore and proxmal core regions of hepatitis B virus in serum from Korean patients with hepatocellular carcinoma
pp. 161-161(1)
Authors: Park Y.-M.; Seung K.Y.; Boo S.K.; Tabor E.

Effects of chronic habitual alcohol intake on the development and serum HCV RNA levels in C viral hepatocellular carcinoma
pp. 161-161(1)
Authors: Kishimoto Y.; Suou T.; Yamamoto T.; Horie Y.; Kobayashi J.; Matsuda H.; Tanaka H.; Kawasaki H.

Long term study on the hepatic functional reserve of patients with hepatocellular carcinoma - assessment by maximal removal rate of indocyanine green
pp. 161-161(1)
Authors: Maeda Y.; Kawata S.; Inui Y.; Fukuda K.; Matsuda Y.; Ito N.; Inada M.; Tamura S.; Imai Y.; Matsuzawa Y.

Effects of hepatitis B virus infection and cigarette smoking on hepatocarcinogenesis among patients with heptitis C virus-related chronic liver diseases; a prospective observation and multivariate analysis of 412 patients.
pp. 162-162(1)
Authors: Chiba T.; Matsuzaki Y.; Tanaka N.; Shoda J.; Abei M.; Osuga T.

The recurrence of hepatocellular carcinoma by hepatitis virus
pp. 162-162(1)
Authors: Kato N.; Shiina S.; Imamura M.; Kanai F.; Okudaira T.; Teratani T.; Kawabe T.; Ohta S.; Shiratori Y.; Omata M.

Influence of interferon administration on hepatocellular carcinogenesis from viral cirrhosis
pp. 162-162(1)
Authors: Ikeda K.; Saitoh S.; Suzuki Y.; Koida I.; Tsubota A.; Kobayashi M.; Arase Y.; Chayama K.; Murashima N.; Kumada H.

Sustained low serum GPT level below 80 INU in HCV-associated cirrhotic patients by multiagent therapy prevents development of hepatocellular carcinoma
pp. 162-162(1)
Authors: Tarao K.; Ohkawa S.; Tamai S.; Miyakawa K.

Prevalence of hepatitis C antibody in patients with chronic liver diseases and hepatocellular carcinoma in Korea
pp. 163-163(1)
Authors: B. H.H.; S. Y.A.; J. H.S.; Y. N.L.; K. W.K.; Park B.C.

Percutaneous ethanol injection; a role in multidisciprinary treatment of hepatocellular carcinoma
pp. 163-163(1)
Authors: Ito K.; Hyogo H.; Kojima K.; Oba N.; Tohyama K.; Matsuura M.

Intra-tumorous ethanol injection on absolute non-curative HCC operation
pp. 163-163(1)
Authors: Katayama K.; Asahara T.; Hino Y.; Ochi M.; Okamoto Y.; Nakahara H.; Itamoto T.; Marubayashi S.; Ono E.; Dohi K.

Therapeutic modalities for not resectable hepatocellular carcinoma and their estimation
pp. 163-163(1)
Authors: Kurokawa F.; Yamasaki T.; Yasunaga M.; Okita K.

Efficacy of percutaneous acetic acid injection (PAI) alone and PAI following transcatheter hepatic arterial embolization (TAE) for large hepatocellular carcinoma (HCC)
pp. 164-164(1)
Authors: Ohnishi K.; Ohyama N.; Yoshioka H.; Nishiyama J.; Nakajima T.; Nakajima M.; Kameda C.; Ito S.; Fujiwara K.

Difference of recurrent style between TAE alone and TAE plus PEI therapy in small HCC.
pp. 164-164(1)
Authors: Oda T.; Iwata K.; Kitamura Y.; Takeshima M.; Matsunaga H.; Nagano Y.; Kamimura S.; Shijo H.; Okumura M.

Influence of pulsed electric fields to the rat liver
pp. 164-164(1)
Authors: Yoshida T.; Katsurashima T.; Shimotohno H.; Miura Y.; Madarame T.; Suzuki K.; Sato S.

Microwave coagulation therapy for hepatocellular carcinoma associated with liver cirrhosis
pp. 164-164(1)
Authors: Sato M.; Watanabe Y.; Lee T.; Kito K.; Iseki S.; Nakata Y.; Kimura S.; Itoh Y.

Evaluation of administration routes on hepatic extraction ratio of adriamycin using hepatic venous isolation and charcoal hemoperfusion
pp. 165-165(1)
Authors: Tominaga M.; Ku Y.; Shiotani M.; Kitagawa T.; Maeda I.; Kusunoki S.; Muramatsu S.; Kuroda Y.; Saitoh Y.

Repeated arterial infusion chemotherapy using implantable drug delivery system in 100 patients with hepatocellular carcinoma
pp. 165-165(1)
Authors: Ihaya T.; Horie Y.; Kawasaki H.; Sawada S.; Nishimuki E.

Transcatheter arterial embolization therapy for the patient with hepatocellular carcinoma using the left brachial artery approach
pp. 165-165(1)
Authors: Watanabe S.; Miyauchi Y.; Shirai M.; Arima K.; Nishioka M.

Potentiation by amiloride of doxorubicin effect on normal and tumor liver cells ''in vitro''.
pp. 165-165(1)
Authors: de Diego J.P.; Trilla C.; Canero R.G.

Involvement of the activity of the MDR gene product, GP170, with PH_I regulation in rat hepatoma cells ''in vitro''.
pp. 166-166(1)
Authors: Perez de Diego J.; Trilla C.; Canero R.G.

Reduction of hepatic acute phase response after partial hepatectomy in elderly patients
pp. 166-166(1)
Authors: Kimura F.; Suwa T.; Kakizaki S.; Miyazaki M.

The significance of suppressing the cytokinemia in hepatic resection
pp. 166-166(1)
Authors: Shimada M.; Saitoh A.; Kano T.; Matsumata T.

The significance of the change in the value of serum interleukin-8 after hepatic resection
pp. 166-166(1)
Authors: Sasaki Y.; Imaoka S.; Nakano H.; Okamura S.; Aihara T.; Yasuda T.; Nakamori S.; Ohigashi H.; Kameyama M.; Hiratsuka M.; Kabuto T.; Ishikawa O.; Furukawa H.; Iwanaga T.

Evaluation Of The Function Of Residual Liver After Extended Hepatic Resection By Positron Emission Tomography Using ¹¹C-Methionine As Tracer Of Amino Acid Metabolism
pp. 167-167(1)
Authors: Otsuki K.; Enomoto K.; Asano T.; Amano H.; Okazumi S.; Abe Y.; Takayama W.; Sasagawa S.; Ioku S.; Miura H.; Mochizuki R.; Yano Y.; Isono K.

Clinical and biological significance of high interconversion activity of liver mitochondrial -hydroxybutyrate dehydrogenase (-OHBDH)
pp. 167-167(1)
Authors: Yamamoto M.; Fujii H.; Okuda J.; Karikomi K.; Kohno H.; Itakura J.; Nagahori K.; Matsumoto Y.

An experimental study of hepatic resection under in situ hypothermic or normothermic perfusion technique
pp. 167-167(1)
Authors: Takeuchi K.; Ohira M.; Nagai Y.; Yada K.; Nakagawa H.; Yanagawa K.; Ishikawa T.; Yamashita T.; Sowa N.

Effects of dopamine(DOA) and dobtamine (DOB) on liver function after liver resection.
pp. 167-167(1)
Authors: Furuta K.; Yoshida M.; Takahashi T.; Iino Z.; Izumika H.; Kitamura M.; Oonumata O.; Kimua T.; Hiki Y.; Kakita A.

Indication and limitation of repeat hepatectomy for recurrent hepatocellular carcinoma.
pp. 168-168(1)
Authors: Uchida M.; Nagasue N.; Kohno H.; Hayashi T.; Mitsumoto Y.; Ono T.; Yamaguchi H.; Nakamura T.

Changes in serum levels of interleukin-6 & acute phase proteins following hepatic resection
pp. 168-168(1)
Authors: Kimura T.; Takahashi T.; Iino Z.; Ito Y.; Furuta K.; Yoshida M.; Sato K.; Kakita A.

The evaluation of liver damage after hepatectomy by serum hyaluronic acid levels
pp. 168-168(1)
Authors: Yoshidome H.; Miyazaki M.; Itoh H.; Kaiho T.; Ambiru S.; Shimizu H.; Nakajima N.

4 year experience with endoscopic retrograde cholangio - pancreatogram/endoscopic sphincterotomy perforations and it's management.
pp. 168-168(1)
Authors: R. C.; H. S.C.; A. L.H.; H. S.N.

A comparison of single with double abscess drainage for the treatment of large bacterial liver abscess
pp. 169-169(1)
Authors: Yamamoto T.; Kishimoto Y.; Kawasaki H.; Nishimuki E.; Maruyama S.

Liver abscess: evaluation of twentyseven cases
pp. 169-169(1)
Authors: Khan M.; Ahmad N.; Rahman S.; Zaki K.M.J.